WO2000039101A1 - Pyrimidine compounds - Google Patents
Pyrimidine compounds Download PDFInfo
- Publication number
- WO2000039101A1 WO2000039101A1 PCT/GB1999/004325 GB9904325W WO0039101A1 WO 2000039101 A1 WO2000039101 A1 WO 2000039101A1 GB 9904325 W GB9904325 W GB 9904325W WO 0039101 A1 WO0039101 A1 WO 0039101A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- formula
- phenyl
- hydroxy
- alkoxy
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title claims abstract description 49
- -1 hydroxy, nitro, amino, cyano, mercapto, carboxy, sulphamoyl Chemical group 0.000 claims abstract description 382
- 125000001424 substituent group Chemical group 0.000 claims abstract description 117
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 150000002148 esters Chemical class 0.000 claims abstract description 52
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 51
- 238000001727 in vivo Methods 0.000 claims abstract description 44
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 31
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 148
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 91
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 77
- 125000005843 halogen group Chemical group 0.000 claims description 62
- 229910052757 nitrogen Inorganic materials 0.000 claims description 53
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 52
- 238000006243 chemical reaction Methods 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 34
- 150000001721 carbon Chemical group 0.000 claims description 33
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 29
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000005864 Sulphur Chemical group 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 23
- 239000001301 oxygen Chemical group 0.000 claims description 23
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000004076 pyridyl group Chemical group 0.000 claims description 19
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 18
- 125000001153 fluoro group Chemical group F* 0.000 claims description 18
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 125000006239 protecting group Chemical group 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 11
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 11
- 230000001093 anti-cancer Effects 0.000 claims description 10
- 239000012038 nucleophile Substances 0.000 claims description 10
- 125000000335 thiazolyl group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 8
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 7
- 229920002554 vinyl polymer Polymers 0.000 claims description 7
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 125000005493 quinolyl group Chemical group 0.000 claims description 6
- 229910052727 yttrium Inorganic materials 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 5
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical group CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 229910052702 rhenium Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
- MEIJADBULOETOV-UHFFFAOYSA-N 1-[4-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1NC1=NC=C(Br)C(NC=2C=CC=CC=2)=N1 MEIJADBULOETOV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
- PTICMNVLTWPRGJ-UHFFFAOYSA-N 1-[4-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenoxy]-2-methyl-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC(OCC(C)(O)CNC(C)C)=CC=C1NC1=NC=C(Br)C(NC=2C=CC=CC=2)=N1 PTICMNVLTWPRGJ-UHFFFAOYSA-N 0.000 claims 1
- MYNGCTJURAGEGJ-UHFFFAOYSA-N 1-[4-[[5-bromo-4-(pyridin-2-ylamino)pyrimidin-2-yl]amino]phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1NC1=NC=C(Br)C(NC=2N=CC=CC=2)=N1 MYNGCTJURAGEGJ-UHFFFAOYSA-N 0.000 claims 1
- JFLMDIJIRXAIJE-UHFFFAOYSA-N 1-[4-[[5-bromo-4-[(6-methylpyridin-2-yl)amino]pyrimidin-2-yl]amino]phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1NC1=NC=C(Br)C(NC=2N=C(C)C=CC=2)=N1 JFLMDIJIRXAIJE-UHFFFAOYSA-N 0.000 claims 1
- OHDQHRAKDCCIMS-UHFFFAOYSA-N 1-[4-[[5-bromo-4-[n-(4,4,4-trifluorobutyl)anilino]pyrimidin-2-yl]amino]phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1NC1=NC=C(Br)C(N(CCCC(F)(F)F)C=2C=CC=CC=2)=N1 OHDQHRAKDCCIMS-UHFFFAOYSA-N 0.000 claims 1
- CUZJLUPYJQKDMI-UHFFFAOYSA-N 5-bromo-2-n-[4-(3-imidazol-1-ylpropoxy)phenyl]-4-n-(6-methylpyridin-2-yl)pyrimidine-2,4-diamine Chemical compound CC1=CC=CC(NC=2C(=CN=C(NC=3C=CC(OCCCN4C=NC=C4)=CC=3)N=2)Br)=N1 CUZJLUPYJQKDMI-UHFFFAOYSA-N 0.000 claims 1
- KYUBMNRBZBDRMB-UHFFFAOYSA-N 5-bromo-4-n-phenyl-2-n-[4-[3-(propan-2-ylamino)propoxy]phenyl]pyrimidine-2,4-diamine Chemical compound C1=CC(OCCCNC(C)C)=CC=C1NC1=NC=C(Br)C(NC=2C=CC=CC=2)=N1 KYUBMNRBZBDRMB-UHFFFAOYSA-N 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 230
- 230000008569 process Effects 0.000 abstract description 31
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 120
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 90
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 239000000243 solution Substances 0.000 description 75
- 239000000047 product Substances 0.000 description 67
- 238000004949 mass spectrometry Methods 0.000 description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 55
- 239000000203 mixture Substances 0.000 description 44
- 238000001704 evaporation Methods 0.000 description 42
- 230000008020 evaporation Effects 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- 239000000463 material Substances 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 28
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 239000007787 solid Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000000543 intermediate Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 21
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 20
- 230000002401 inhibitory effect Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 125000004429 atom Chemical group 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 239000003112 inhibitor Substances 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 230000022131 cell cycle Effects 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000016736 Cyclin Human genes 0.000 description 12
- 108050006400 Cyclin Proteins 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- RKALDJKOJAJFIK-UHFFFAOYSA-N 1-(4-aminophenoxy)-3-(dimethylamino)propan-2-ol;hydrochloride Chemical compound Cl.CN(C)CC(O)COC1=CC=C(N)C=C1 RKALDJKOJAJFIK-UHFFFAOYSA-N 0.000 description 11
- BBZMLGAPOLIUJN-UHFFFAOYSA-N 1-[4-[[4-anilino-5-(ethoxymethyl)pyrimidin-2-yl]amino]phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound N1=C(NC=2C=CC=CC=2)C(COCC)=CN=C1NC1=CC=C(OCC(O)CN(C)C)C=C1 BBZMLGAPOLIUJN-UHFFFAOYSA-N 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 125000001246 bromo group Chemical group Br* 0.000 description 11
- 125000001309 chloro group Chemical group Cl* 0.000 description 11
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 11
- 239000000377 silicon dioxide Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 10
- NKUZAJOBLJQQPW-UHFFFAOYSA-N 5-bromo-2-chloro-n-phenylpyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NC=2C=CC=CC=2)=N1 NKUZAJOBLJQQPW-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 150000001448 anilines Chemical class 0.000 description 10
- 125000002619 bicyclic group Chemical group 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 9
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 8
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 150000002431 hydrogen Chemical group 0.000 description 7
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 6
- 108010039627 Aprotinin Proteins 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 229960004405 aprotinin Drugs 0.000 description 6
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 6
- 239000002198 insoluble material Substances 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 6
- 108010052968 leupeptin Proteins 0.000 description 6
- 239000012139 lysis buffer Substances 0.000 description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 0 *c1cnc(NC2CCCCCCC(C*(C3*C3)=C)CCCCCCC2)nc1N(*)C1CCCCCCCCCCC1 Chemical compound *c1cnc(NC2CCCCCCC(C*(C3*C3)=C)CCCCCCC2)nc1N(*)C1CCCCCCCCCCC1 0.000 description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 201000000582 Retinoblastoma Diseases 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 4
- SITWGQSSCPXDIZ-UHFFFAOYSA-N 2-chloro-5-iodo-n-phenylpyrimidin-4-amine Chemical compound ClC1=NC=C(I)C(NC=2C=CC=CC=2)=N1 SITWGQSSCPXDIZ-UHFFFAOYSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
- MRDMAZWNGRESOO-UHFFFAOYSA-N 4-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenol Chemical compound C1=CC(O)=CC=C1NC1=NC=C(Br)C(NC=2C=CC=CC=2)=N1 MRDMAZWNGRESOO-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 239000002841 Lewis acid Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 150000007517 lewis acids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 125000006308 propyl amino group Chemical group 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000011775 sodium fluoride Substances 0.000 description 4
- 235000013024 sodium fluoride Nutrition 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- MBHQWSSJIBMVIA-UHFFFAOYSA-N 1-(4-aminophenoxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NCC(O)COC1=CC=C(N)C=C1 MBHQWSSJIBMVIA-UHFFFAOYSA-N 0.000 description 3
- QAVCQCQQTYJKSO-UHFFFAOYSA-N 2-chloro-11-cyclopropyl-4-methyl-5h-dipyrido[2,3-b:2',3'-f][1,4]diazepin-6-one Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC(Cl)=NC=2N1C1CC1 QAVCQCQQTYJKSO-UHFFFAOYSA-N 0.000 description 3
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000003909 Cyclin E Human genes 0.000 description 3
- 108090000257 Cyclin E Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000005909 Kieselgur Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 241000256251 Spodoptera frugiperda Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- ICSNLGPSRYBMBD-UHFFFAOYSA-N alpha-aminopyridine Natural products NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- MMCPOSDMTGQNKG-UHFFFAOYSA-N anilinium chloride Chemical compound Cl.NC1=CC=CC=C1 MMCPOSDMTGQNKG-UHFFFAOYSA-N 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 238000007080 aromatic substitution reaction Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 102000057090 human PTK2 Human genes 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- CUYKNJBYIJFRCU-UHFFFAOYSA-N pyridine-3-amine Natural products NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 3
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 description 2
- FPIGOBKNDYAZTP-UHFFFAOYSA-N 1,2-epoxy-3-(4-nitrophenoxy)propane Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1OC1 FPIGOBKNDYAZTP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LIBYGKUWXRBMPA-UHFFFAOYSA-N 1-(3-bromopropoxy)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(OCCCBr)C=C1 LIBYGKUWXRBMPA-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 2
- QUKSCHBDZALOEU-UHFFFAOYSA-N 2,5-dichloro-n-phenylpyrimidin-4-amine Chemical compound ClC1=CN=C(Cl)N=C1NC1=CC=CC=C1 QUKSCHBDZALOEU-UHFFFAOYSA-N 0.000 description 2
- XGUQAVRRXINQMV-UHFFFAOYSA-N 3-[(4-anilino-5-bromopyrimidin-2-yl)amino]phenol Chemical compound OC1=CC=CC(NC=2N=C(NC=3C=CC=CC=3)C(Br)=CN=2)=C1 XGUQAVRRXINQMV-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- QWIXGBGZNOAXJH-UHFFFAOYSA-N 4-anilino-2-methylsulfonylpyrimidine-5-carbonitrile Chemical compound CS(=O)(=O)C1=NC=C(C#N)C(NC=2C=CC=CC=2)=N1 QWIXGBGZNOAXJH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010051113 Arterial restenosis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940102253 isopropanolamine Drugs 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HVSHSQSBIWZAPH-UHFFFAOYSA-N (4-anilino-2-chloropyrimidin-5-yl)-phenylmethanol Chemical compound C=1N=C(Cl)N=C(NC=2C=CC=CC=2)C=1C(O)C1=CC=CC=C1 HVSHSQSBIWZAPH-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- ILROLYQPRYHHFG-UHFFFAOYSA-N 1-$l^{1}-oxidanylprop-2-en-1-one Chemical group [O]C(=O)C=C ILROLYQPRYHHFG-UHFFFAOYSA-N 0.000 description 1
- MOFFXTVASRRMEG-UHFFFAOYSA-N 1-(4-amino-n-methylanilino)-3-(dimethylamino)propan-2-ol Chemical compound CN(C)CC(O)CN(C)C1=CC=C(N)C=C1 MOFFXTVASRRMEG-UHFFFAOYSA-N 0.000 description 1
- ZHZFXLGGTDVUFJ-UHFFFAOYSA-N 1-(4-aminophenoxy)-2-methyl-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NCC(C)(O)COC1=CC=C(N)C=C1 ZHZFXLGGTDVUFJ-UHFFFAOYSA-N 0.000 description 1
- BLOZPOZETDEMRB-UHFFFAOYSA-N 1-(4-aminophenoxy)-3-(tert-butylamino)propan-2-ol Chemical compound CC(C)(C)NCC(O)COC1=CC=C(N)C=C1 BLOZPOZETDEMRB-UHFFFAOYSA-N 0.000 description 1
- XGLCTRQIEGPEPR-UHFFFAOYSA-N 1-(4-aminophenoxy)-3-ethoxypropan-2-ol Chemical compound CCOCC(O)COC1=CC=C(N)C=C1 XGLCTRQIEGPEPR-UHFFFAOYSA-N 0.000 description 1
- PCCRZPIJPREQTI-UHFFFAOYSA-N 1-(dimethylamino)-3-(4-nitrophenoxy)propan-2-ol Chemical compound CN(C)CC(O)COC1=CC=C([N+]([O-])=O)C=C1 PCCRZPIJPREQTI-UHFFFAOYSA-N 0.000 description 1
- AYPGLYYFPLTSTF-UHFFFAOYSA-N 1-(dimethylamino)-3-(n-methyl-4-nitroanilino)propan-2-ol Chemical compound CN(C)CC(O)CN(C)C1=CC=C([N+]([O-])=O)C=C1 AYPGLYYFPLTSTF-UHFFFAOYSA-N 0.000 description 1
- REKRTOCQZVCOJB-UHFFFAOYSA-N 1-[4-[(5-amino-4-anilinopyrimidin-2-yl)amino]phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1NC1=NC=C(N)C(NC=2C=CC=CC=2)=N1 REKRTOCQZVCOJB-UHFFFAOYSA-N 0.000 description 1
- FWSKLCLBCYNSRG-UHFFFAOYSA-N 1-[4-[[5-bromo-4-(2-fluoro-5-methylanilino)pyrimidin-2-yl]amino]phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1NC1=NC=C(Br)C(NC=2C(=CC=C(C)C=2)F)=N1 FWSKLCLBCYNSRG-UHFFFAOYSA-N 0.000 description 1
- XMZJZQPEPUHFEL-UHFFFAOYSA-N 1-[4-[[5-bromo-4-(4-bromoanilino)pyrimidin-2-yl]amino]phenoxy]-3-(dimethylamino)propan-2-ol Chemical compound C1=CC(OCC(O)CN(C)C)=CC=C1NC1=NC=C(Br)C(NC=2C=CC(Br)=CC=2)=N1 XMZJZQPEPUHFEL-UHFFFAOYSA-N 0.000 description 1
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- JWVTWJNGILGLAT-UHFFFAOYSA-N 1-ethenyl-4-fluorobenzene Chemical compound FC1=CC=C(C=C)C=C1 JWVTWJNGILGLAT-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 1
- QBJROQVPLXMPHP-UHFFFAOYSA-N 2,4-dichloro-n-propan-2-ylpyrimidine-5-carboxamide Chemical compound CC(C)NC(=O)C1=CN=C(Cl)N=C1Cl QBJROQVPLXMPHP-UHFFFAOYSA-N 0.000 description 1
- VVHFXJOCUKBZFS-UHFFFAOYSA-N 2-(chloromethyl)-2-methyloxirane Chemical compound ClCC1(C)CO1 VVHFXJOCUKBZFS-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- 150000003930 2-aminopyridines Chemical class 0.000 description 1
- GKNGDJAGDPAQHO-UHFFFAOYSA-N 2-bromo-6-methylpyridin-4-amine Chemical compound CC1=CC(N)=CC(Br)=N1 GKNGDJAGDPAQHO-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- YFGQRNCTQLOXDU-UHFFFAOYSA-N 2-chloro-5-(ethoxymethyl)-n-phenylpyrimidin-4-amine Chemical compound CCOCC1=CN=C(Cl)N=C1NC1=CC=CC=C1 YFGQRNCTQLOXDU-UHFFFAOYSA-N 0.000 description 1
- JBZZOPATIMMMEM-UHFFFAOYSA-N 2-chloro-5-(furan-3-yl)-n-phenylpyrimidin-4-amine Chemical compound C=1C=CC=CC=1NC1=NC(Cl)=NC=C1C=1C=COC=1 JBZZOPATIMMMEM-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- HLQKICNSXKMRHG-UHFFFAOYSA-N 2-chloro-n-phenyl-5-(2-phenylethynyl)pyrimidin-4-amine Chemical compound C=1C=CC=CC=1NC1=NC(Cl)=NC=C1C#CC1=CC=CC=C1 HLQKICNSXKMRHG-UHFFFAOYSA-N 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- WBSXBZKLIYUBCI-UHFFFAOYSA-N 2-methyl-1-(4-nitrophenoxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NCC(C)(O)COC1=CC=C([N+]([O-])=O)C=C1 WBSXBZKLIYUBCI-UHFFFAOYSA-N 0.000 description 1
- YPZHFKJXJPXHIW-UHFFFAOYSA-N 2-n-[3-(propan-2-ylamino)propyl]pyridine-2,5-diamine Chemical compound CC(C)NCCCNC1=CC=C(N)C=N1 YPZHFKJXJPXHIW-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- 150000003929 3-aminopyridines Chemical class 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- RXNNHSKCCHGJQM-UHFFFAOYSA-N 4,6-dichloropyrimidine-5-carbonyl chloride Chemical compound ClC(=O)C1=C(Cl)N=CN=C1Cl RXNNHSKCCHGJQM-UHFFFAOYSA-N 0.000 description 1
- AFRDTKWHTKFULR-UHFFFAOYSA-N 4-(2-imidazol-1-ylethoxy)aniline Chemical compound C1=CC(N)=CC=C1OCCN1C=NC=C1 AFRDTKWHTKFULR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QHHRYLOOBJERHA-UHFFFAOYSA-N 4-[(4-anilino-5-bromopyrimidin-2-yl)amino]-3-fluorophenol Chemical compound FC1=CC(O)=CC=C1NC1=NC=C(Br)C(NC=2C=CC=CC=2)=N1 QHHRYLOOBJERHA-UHFFFAOYSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- BOWGVWDAJPPVQQ-UHFFFAOYSA-N 4-anilino-2-methylsulfanylpyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(NC=2C=CC=CC=2)=N1 BOWGVWDAJPPVQQ-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- IGIRTCCCRNZFSQ-UHFFFAOYSA-N 4-chloro-2-methylsulfanylpyrimidine-5-carbonitrile Chemical compound CSC1=NC=C(C#N)C(Cl)=N1 IGIRTCCCRNZFSQ-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- VCIIOHBUMCUELI-UHFFFAOYSA-N 5-benzyl-2-chloro-n-phenylpyrimidin-4-amine Chemical compound C=1C=CC=CC=1NC1=NC(Cl)=NC=C1CC1=CC=CC=C1 VCIIOHBUMCUELI-UHFFFAOYSA-N 0.000 description 1
- DXWNFHHNJGEQDP-UHFFFAOYSA-N 5-bromo-2-chloro-n-(2,3-dihydro-1h-inden-5-yl)pyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NC=2C=C3CCCC3=CC=2)=N1 DXWNFHHNJGEQDP-UHFFFAOYSA-N 0.000 description 1
- YJZMXVMJQIKYJJ-UHFFFAOYSA-N 5-bromo-2-chloro-n-(6-methylpyridin-2-yl)pyrimidin-4-amine Chemical compound CC1=CC=CC(NC=2C(=CN=C(Cl)N=2)Br)=N1 YJZMXVMJQIKYJJ-UHFFFAOYSA-N 0.000 description 1
- AHIBUJPDFMVTEU-UHFFFAOYSA-N 5-bromo-2-chloro-n-pyridin-2-ylpyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NC=2N=CC=CC=2)=N1 AHIBUJPDFMVTEU-UHFFFAOYSA-N 0.000 description 1
- IOUJPJLMBMBLDH-UHFFFAOYSA-N 5-bromo-2-chloro-n-pyridin-3-ylpyrimidin-4-amine Chemical compound ClC1=NC=C(Br)C(NC=2C=NC=CC=2)=N1 IOUJPJLMBMBLDH-UHFFFAOYSA-N 0.000 description 1
- KWDUFOGQKWRHDP-UHFFFAOYSA-N 5-bromo-2-n-[2-fluoro-4-(oxiran-2-ylmethoxy)phenyl]-4-n-phenylpyrimidine-2,4-diamine Chemical compound C=1C=C(NC=2N=C(NC=3C=CC=CC=3)C(Br)=CN=2)C(F)=CC=1OCC1CO1 KWDUFOGQKWRHDP-UHFFFAOYSA-N 0.000 description 1
- LWLBWEZNBKCBRL-UHFFFAOYSA-N 5-bromo-2-n-[4-(oxiran-2-ylmethoxy)phenyl]-4-n-phenylpyrimidine-2,4-diamine Chemical compound N1=C(NC=2C=CC=CC=2)C(Br)=CN=C1NC(C=C1)=CC=C1OCC1CO1 LWLBWEZNBKCBRL-UHFFFAOYSA-N 0.000 description 1
- ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
- BMCNRZAESJUHJU-UHFFFAOYSA-N 5-ethoxy-1h-pyrimidine-2,4-dione Chemical compound CCOC1=CNC(=O)NC1=O BMCNRZAESJUHJU-UHFFFAOYSA-N 0.000 description 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101000606657 Arabidopsis thaliana Peroxidase 56 Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FVNBYTHYJRKUJH-UHFFFAOYSA-N N-[(carbamoylamino)-methylamino]formamide Chemical compound O=CNN(C)NC(N)=O FVNBYTHYJRKUJH-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- DJPVONPSNBLDSU-UHFFFAOYSA-A [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DJPVONPSNBLDSU-UHFFFAOYSA-A 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000005002 aryl methyl group Chemical group 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- CWBHKBKGKCDGDM-UHFFFAOYSA-N bis[(2,2,2-trifluoroacetyl)oxy]boranyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OB(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F CWBHKBKGKCDGDM-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- QDEOKXOYHYUKMS-UHFFFAOYSA-N but-3-ynylbenzene Chemical compound C#CCCC1=CC=CC=C1 QDEOKXOYHYUKMS-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- XEKAUTDWPYQNFU-UHFFFAOYSA-N chlorane Chemical compound Cl.Cl.Cl XEKAUTDWPYQNFU-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000026374 cyclin catabolic process Effects 0.000 description 1
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- RPOWBFPRLOVIKW-UHFFFAOYSA-N ethyl 4-anilino-2-[4-[3-(dimethylamino)-2-hydroxypropoxy]anilino]pyrimidine-5-carboxylate Chemical compound N1=C(NC=2C=CC=CC=2)C(C(=O)OCC)=CN=C1NC1=CC=C(OCC(O)CN(C)C)C=C1 RPOWBFPRLOVIKW-UHFFFAOYSA-N 0.000 description 1
- WYCPAQRFAYXWAI-UHFFFAOYSA-N ethyl 4-anilino-2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1NC1=CC=CC=C1 WYCPAQRFAYXWAI-UHFFFAOYSA-N 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- QYRFJLLXPINATB-UHFFFAOYSA-N hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride Chemical class Cl.Cl.NC1=C(F)C(N)=C(F)C(F)=C1F QYRFJLLXPINATB-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- KGVPNLBXJKTABS-UHFFFAOYSA-N hymexazol Chemical compound CC1=CC(O)=NO1 KGVPNLBXJKTABS-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- CLSCMGNKVZWNAN-UHFFFAOYSA-N n-(4-bromophenyl)-2,5-dichloropyrimidin-4-amine Chemical compound ClC1=CN=C(Cl)N=C1NC1=CC=C(Br)C=C1 CLSCMGNKVZWNAN-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- XIFJZJPMHNUGRA-UHFFFAOYSA-N n-methyl-4-nitroaniline Chemical compound CNC1=CC=C([N+]([O-])=O)C=C1 XIFJZJPMHNUGRA-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- VBTCAHMANZTRMG-UHFFFAOYSA-N prop-2-ynylcyclopentane Chemical compound C#CCC1CCCC1 VBTCAHMANZTRMG-UHFFFAOYSA-N 0.000 description 1
- TURAMGVWNUTQKH-UHFFFAOYSA-N propa-1,2-dien-1-one Chemical group C=C=C=O TURAMGVWNUTQKH-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 229960002901 sodium glycerophosphate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 238000003210 sulforhodamine B staining Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 101150061166 tetR gene Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000013715 transcription antitermination Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the invention relates to pyrimidine derivatives, or pharmaceutically acceptable salts or in vivo hydro lysable esters thereof, which possess cell-cycle inhibitory activity and are accordingly useful for their anti-cancer (such as anti-cell-proliferative, anti-cell migration and/or apoptotic) activity and are therefore useful in methods of treatment of the human or animal body.
- the invention also relates to processes for the manufacture of said pyrimidine derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments or use in the production of an anti-cancer (anti-cell-proliferation/migration and/or apoptotic) effect in a warm-blooded animal such as man.
- Cyclins A family of intracellular proteins called cyclins play a central role in the cell cycle. The synthesis and degradation of cyclins is tightly controlled such that their level of expression fluctuates during the cell cycle. Cyclins bind to cyclin-dependent serine/threonine kinases (CDKs) and this association is essential for CDK (such as CDK1, CDK2, CDK4 and/or CDK6) activity within the cell. Although the precise details of how each of these factors combine to regulate CDK activity is poorly understood, the balance between the two dictates whether or not the cell will progress through the cell cycle.
- CDKs cyclin-dependent serine/threonine kinases
- CDKs appear to be downstream of a number of oncogene signalling pathways.
- Disregulation of CDK activity by upregulation of cyclins and/or deletion of endogenous inhibitors appears to be an important axis between mitogenic signalling pathways and proliferation of tumour cells. Accordingly it has been recognised that an inhibitor of cell cycle kinases, particularly inhibitors of CDK2, CDK4 and/or CDK6 (which operate at the S-phase, Gl-S and Gl-S phase respectively) should be of value as a selective inhibitor of cell proliferation, such as growth of mammalian cancer cells.
- FAK focal adhesion kinase
- apoptosis cell-death
- an inhibitor of FAK may therefore have value as an anti-cancer agent.
- the present invention is based on the discovery that certain 2,4-pyrimidine compounds surprisingly inhibit the effects of cell cycle kinases showing selectivity for CDK2, CDK4 and CDK6, and also inhibit FAK and thus possess anti-cancer (anti-cell-migration/proliferation and/or apoptotic) properties.
- Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumours and leukemias), fibroprohferative and differentiative disorders , psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
- cancers solid tumours and leukemias
- fibroprohferative and differentiative disorders psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
- R 1 is selected from hydrogen, C ⁇ alkyl [optionally substituted by one or two substituents independently selected from halo, amino, C,_ 4 alkylamino, di-(C M alkyl)amino, hydroxy, cyano, C,. 4 alkoxy, C,. 4 alkoxycarbonyl, carbamoyl, -NHCOC,.
- R is selected from halo, hydroxy, nitro, amino, cyano, mercapto, carboxy, sulphamoyl, formamido, ureido or carbamoyl or a group of formula (lb): A-B-C-
- A is C,_ 6 alkyl, C 2 _ 6 alkenyl, C 2 . 6 alkynyl, C 3 _ 8 cycloalkyl, phenyl, heterocycle or heteroaryl, wherein said C,_ 5 alkyl, C 3 . 6 alkenyl and C 3 . 6 alkynyl are optionally substituted by one or more substituents selected from halo, nitro, cyano, amino, hydroxy, mercapto, carboxy, formamido, ureido, C,. 3 alkylamino, di-(C,. 3 alkyl)amino, C,. 3 alkoxy, trifluoromethyl, C 3 .
- any phenyl, C 3 _ 8 cycloalkyl, heterocycle or heteroaryl may be optionally substituted by one or more halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, formamido, ureido, sulphamoyl, C alkyl, C 2 . 4 alkenyl, C 2 . 4 alkynyl, C,. 4 alkoxy, C M alkanoyl, C alkanoyloxy, C,.
- B is -O-, -S-, -C(O)-, - ⁇ H-, -N(C,. 4 alkyl)-, -C(O)NH-, -C(O)N(C,. 4 alkyl)-, -NHC(O)-, -N(C M alkyl)C(O)- or B is a direct bond;
- C is C,. 4 alkylene or a direct bond;
- Q, and Q 2 are independently selected from aryl, a 5- or 6-membered monocyclic moiety (linked via a ring carbon atom and containing one to three heteroatoms independently selected from nitrogen, oxygen and sulphur); and a 9- or 10-membered bicyclic heterocyclic moiety (linked via a ring carbon atom and containing one or two nitrogen heteroatoms and optionally containing a further one or two heteroatoms selected from nitrogen, oxygen and sulphur); and one or both of Q, and Q 2 bears on any available carbon atom one substituent of the formula (la) and Q, may optionally bear on any available carbon atom further substituents of the formula (la):
- X is -CH 2 -, -O-, -NH-, -NR y - or -S- [wherein R y is C,. 4 alkyl, optionally substituted by one substituent selected from halo, amino, cyano, C M alkoxy or hydroxy]; Y 1 is H, C,. 4 alkyl or as defined for Z; Y 2 is H or C alkyl; Z is RO-, R b R c N-, R d S-, R e R f NNR g -, a nitrogen linked heteroaryl or a nitrogen linked heterocycle [wherein said heterocycle is optionally substituted on a ring carbon or a ring nitrogen by C alkyl or C,.
- R a , R b , R c , R d , R e , R f and R are independently selected from hydrogen, C,. 4 alkyl, C 2 . 4 alkenyl, C 3 _ s cycloalkyl, and wherein said C alkyl and C 2 _ 4 alkenyl are optionally substituted by one or more phenyl ; n is 1, 2 or 3; m is 1, 2 or 3; and Q, may optionally bear on any available carbon atom up to four substituents independently selected from halo, thio, nitro, carboxy, cyano, C 2 _ 4 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C 2 _ 4 alkynyl, C,.
- Q 2 may optionally bear on any available carbon atom up to four substituents independently selected from halo, hydroxy, thio, nitro, carboxy, cyano, C 2 . 4 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C 2.4 alkynyl, C,. 5 alkanoyl, C M alkoxycarbonyl, C,. 6 alkyl, hydroxy-C, .3 alkyl, fluoro-C ⁇ _ 4 alkyl, amino-C,. 3 alkyl, C,. 4 alkylamino-C,. 3 alkyl, di-(C ] .
- a suitable value for "heterocycle” within the definition of A in group (lb) is a fully saturated, mono or bicyclic ring that contains 4-12 atoms, at least one of which is selected from nitrogen, sulphur or oxygen, wherein a -CH 2 - group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form S-oxide(s).
- heterocycle is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
- “Heterocycle” may be nitrogen or carbon linked.
- heterocycle examples include mo ⁇ holino, piperidyl, piperazinyl, pyrrolidinyl, thiomo ⁇ holino, homopiperazinyl, imidazolyl, imidazolidinyl, pyrazolidinyl, dioxanyl and dioxolanyl.
- heterocycle is mo ⁇ holine, piperidyl, piperazinyl, pyrrolidinyl, thiomo ⁇ holine or homopiperazinyl. More preferably "heterocycle” is mo ⁇ holino.
- a suitable value for "heteroaryl” within the definition of A in group (lb) is a partially unsaturated or fully unsaturated, mono or bicyclic ring that contains 4-12 atoms, at least one of which is selected from nitrogen, sulphur or oxygen, wherein a -CH 2 - group can optionally be replaced by a -C(O)-, and a ring sulphur and/or nitrogen atom may be optionally oxidised to form S-oxide(s) and/or an ⁇ -oxide.
- heteroaryl is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
- Heteroaryl may be nitrogen or carbon linked (but only nitrogen linked if the nitrogen link results in a neutral compound being formed). Suitable values for “heteroaryl” include thienyl, furyl, imidazolyl, thiazolyl, thiadiazolyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, triazinyl, pyrrolyl or pyrazolyl. Preferably "heteroaryl” is furyl, imidazolyl, thiazolyl, isoxazolyl, benzothienyl, quinolinyl, tetrazolyl and pyrazolyl.
- heteroaryl is imidazol-1-yl, fur-3-yl, isoxazol-3-yl, benzothien-6-yl, quinolin-6-yl, pyrazol-3-yl, thiazol-2-yl or tetrazol-5-yl.
- a suitable value for Z in group (la) when it is a "nitrogen linked heteroaryl” is a mono or bicyclic ring that has a degree of unsaturation, containing 4-12 atoms, at least one of which is selected from nitrogen, and optionally 1-3 further atoms are selected from nitrogen, sulphur or oxygen, wherein a -CH 2 - group can optionally be replaced by a -C(O)-, and a ring sulphur and/or nitrogen atom may be optionally oxidised to form S-oxide(s) and/or an N-oxide.
- nitrogen linked heteroaryl is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. The nitrogen link results in a neutral compound being formed.
- Suitable values for "nitrogen linked heteroaryl” include imidazol-1-yl, pyrrolin-1-yl, imidazolin-1-yl, pyrazolin-1-yl, triazol-1-yl, indol-1-yl, isoindol-2-yl, indolin-1-yl, benzimidazol-1-yl, pyrrol- 1-yl or pyrazol-1-yl.
- nitrogen linked heteroaryl is imidazol-1-yl.
- a suitable value for Z in group (la) when it is a "nitrogen linked heterocycle” is an unsaturated mono or bicyclic ring that contains 4-12 atoms, at least one of which is selected from nitrogen, and optionally 1-3 further atoms are selected from nitrogen, sulphur or oxygen, wherein a -CH 2 - group can optionally be replaced by a -C(O)-, and a ring sulphur may be optionally oxidised to form S-oxide(s).
- nitrogen linked heterocycle is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms.
- Suitable values for "nitrogen linked heterocycle” include pyrrolidin-1-yl, piperidino, piperazin-1-yl, mo ⁇ holino, thiomo ⁇ holino, homopiperidin-y-1 or homopiperazin-1-yl.
- a “nitrogen linked heterocycle” is pyrrolidin-1-yl, piperazin-1-yl or mo ⁇ holino.
- a suitable value for Q, and Q 2 when it is a 5- or 6-membered monocyclic moiety containing one to three heteroatoms independently selected from nitrogen, oxygen and sulphur, or a 9- or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further one or two heteroatoms selected from nitrogen, oxygen and sulphur; is an aromatic heterocycle, for example, pyrrole, furan, thiophene, imidazole, oxazole, isoxazole, thiazole, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, p-isoxazine, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl or naphthyridinyl, indole, isoindazole, benzoxazole, benzimid
- Q is a 5- or 6-membered monocyclic moiety containing one to three heteroatoms independently selected from nitrogen, oxygen and sulphur
- Q is linked to the pyrimidine ring in such a way that when Q, bears a substituent of the formula (la) or (la') the substituent of formula (la) or (la') is not adjacent to the -NH- link.
- l,2,3-triazol-4-yl or l,2,3-triazol-5-yl are not suitable values for Q, when Q, bears a substituent of the formula (la) or (la').
- Q, or Q 2 is a 9- or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms it will be appreciated that Q, or Q 2 may be attached from either of the two rings of the bicyclic heterocyclic moiety.
- Q, or Q 2 is a 5- or 6-membered monocyclic moiety or a 9- or 10-membered bicyclic heterocyclic moiety it is, for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 2-quinolyl, 3-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 3-cinnolyl, 6-cinnolyl, 7-cinnolyl, 2-quinazolinyl, 4-quinazolinyl, 6-quinazolinyl, 7-quinazolinyl, 2-quinoxalinyl, 5-quinoxalinyl, 6-quinoxalinyl
- Q, or Q 2 is a 5- or 6-membered monocyclic moiety or a 9- or 10-membered bicyclic heterocyclic moiety it is pyridyl, indazolyl, indolyl, quinolyl, pyrazolyl or thiazolyl. More particularly 2-pyridyl, 3- ⁇ yridyl, 4-pyridyl, lH-5-indazolyl, 5-indolyl, 6-quinolyl, 3-pyrazolyl or 2-thiazolyl.
- a suitable value for Q, and Q 2 when it is "aryl" is a fully or partially unsaturated, mono or bicyclic carbon ring that contains 4-12 atoms.
- aryl is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for “aryl” include phenyl, naphthyl, tetralinyl or indanyl. Particularly “aryl” is phenyl, naphthyl or indanyl. More particularly “aryl” is phenyl or indanyl.
- a suitable value for a ring substituent when it is a 5- or 6-membered aromatic heterocycle is, for example, pyrrole, furan, thiophene, imidazole, oxazole, isoxazole, thiazole, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or p-isoxazine.
- alkyl includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl” are specific for the straight chain version only. An analogous convention applies to other generic terms.
- Suitable values for the generic radicals (such as in R 1 and in substituents on Q, and Q 2 and also those in R x ) referred to above include those set out below: - when it is halo is, for example, fluoro, chloro, bromo and iodo; C 2.4 alkenyl is, for example, vinyl and allyl; C 2 . 6 alkenyl is, for example, vinyl and allyl; when it is C 3.5 alkenyl is, for example, allyl; when it is C 3 5 alkynyl is, for example, propyn-2-yl; when it is C 2 .
- alkynyl is, for example, ethynyl and propyn-2-yl
- C 2 . 6 alkynyl is, for example, ethynyl and propyn-2-yl
- 6 alkyl is, for example, cyclopropylmethyl
- when it is C,. 5 alkanoyl is, for example, formyl and acetyl
- when it is C M alkoxycarbonyl is, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and tert-butoxycarbonyl; when it is C,.
- 3 alkyl is, for example, methyl, ethyl, propyl, isopropyl; when it is C,.
- 4 alkyl is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; when it is C,.
- 6 alkyl is, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl or 3-methylbutyl; when it is hydroxy-C l 3 alkyl is, for example, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl and 3-hydroxypropyl; when it is fluoro-C,_ 4 alkyl is, for example, fiuoromethyl, difluoromethyl, trifluoromethyl and 2-fluoroethyl; when it is amino-C,.
- 3 alkyl is, for example, aminomethyl, 1-aminoethyl and 2-aminoethyl; when it is is, for example, methylaminomethyl, ethylaminomethyl, 1-methylaminoethyl, 2-methylaminoethyl, 2-ethylamimoethyl and 3-methylaminopropyl; when it is di-(C,. 4 alkyl)amino-C 1 .
- 3 alkyl is, for example, dimethylaminomethyl, diethylaminomethyl, 1-dimethylaminoethyl, 2-dimethylaminoethyl and 3-dimethylaminopropyl; when it is cyano-C, .4 alkyl is, for example cyanomethyl, 2-cyanoethyl and 3-cyanopropyl; when it is C 2.4 alkanoyloxy-C,.
- 4 -alkyl is, for example, acetoxymethyl, propionyloxymethyl, butyryloxymethyl, 2-acetoxyethyl and 3-acetoxypropyl; when it is C ⁇ alkoxy-C ⁇ alkyl is, for example, methoxymethyl, ethoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 2-ethoxyethyl and 3-methoxypropyl; when it is carboxy-C,. 4 alkyl is, for example carboxymethyl, 1-carboxyethyl, 2-carboxyethyl and 3-carboxypropyl; when it is C,. 4 alkoxycarbonyI-C,.
- 4 alkyl is, for example, methoxycarbonylmethyl, ethoxycarbonylmethyl, tert-butoxycarbonylmethyl, 1 -methoxycarbonylethyl, 1 -ethoxycarbonylethyl, 2-methoxycarbonylethyl, 2-ethoxycarbonylethyl, 3-methoxycarbonylpropyl and 3-ethoxycarbonylpropyl; when it is carbamoyl-C,.
- 4 alkyI is, for example carbamoylmethyl, 1-carbamoylethyl, 2-carbamoylethyl and 3-carbamoylpropyl; when it is N-C,.
- 4 alkylcarbamoyl-C, .4 alkyl is, for example, N-methylcarbamoylmethyl, N-ethylcarbamoylmethyl, N-propylcarbamoylmethyl, 1 -(N-methylcarbamoyl)ethyl, l-(N-ethylcarbamoyl)ethyl, 2-(N-methylcarbamoyl)ethyl, 2-(N-ethylcarbamoyl)ethyl and 3-(N-methylcarbamoyl)propyl; when it is
- 4 alkyl is, for example, N,N-dimethylcarbamoylmethyl, N-ethyl-N-methylcarbamoylmethyl, N,N-diethylcarbamoylmethyl, l-(N,N-dimethylcarbamoyl)ethyl, 1 -(N,N-diethylcarbamoyl)ethyl, 2-(N,N-dimethylcarbamoyl)ethyl, 2-(N,N-diethylcarbamoyl)ethyl and 3-(N,N-dimethylcarbamoyl)propyl; when it is pyrrolidin-l-yl-C ⁇ alkyl is, for example, pyrrolidin-1-ylmethyl and 2-pyrrolidin-l-ylethyl; when it is piperidin-l
- 3 alkyl is, for example, mo ⁇ holinomethyl and 2-mo ⁇ holinoethyl; when it is thiomorpholino-C,. 3 alkyl is, for example, thiomo ⁇ holinomethyl and 2-thiomo ⁇ holinoethyl; when it is imidazo-l-yl-C j ⁇ alkyl is, for example, imidazo-1-ylmethyl and 2-imidazo-l-ylethyl; when it is C,. 4 alkoxy is, for example, methoxy, ethoxy, propoxy, isopropoxy or butoxy; when it is C,.
- 3 alkoxy is, for example, methoxy, ethoxy, propoxy or isopropoxy; when it is cyano-C,. 4 alkoxy is, for example, cyanomethoxy, 1-cyanoethoxy, 2-cyanoethoxy and 3-cyanopropoxy; when it is carbamoyl-C,. 4 alkoxy is, for example, carbamoylmethoxy, 1-carbamoylethoxy, 2-carbamoylethoxy and 3-carbamoylpropoxy; when it is N-C,_ 4 alkyIcarbamoyl-C,.
- 4 alkoxy is, for example, N-methylcarbamoylmethoxy, N-ethylcarbamoylmethoxy, 2-(N-methylcarbamoyl)ethoxy, 2-(N-ethylcarbamoyl)ethoxy and 3-(N-methylcarbamoyl)propoxy; when it is ⁇ yV-di-(C,.
- alkyl)-carbamoyl-C 1.4 alkoxy is, for example, N,N-dimethylcarbamoylmethoxy, N-ethyl-N-methylcarbamoylmethoxy, N,N-diethylcarbamoylmethoxy, 2-(N,N-dimethylcarbamoyl)ethoxy,
- 4 alkoxycarbonyl-C ] is, for example, methoxycarbonylmethoxy, ethoxycarbonylmethoxy, 1 -methoxycarbonylethoxy, 2-methoxycarbonylethoxy, 2-ethoxycarbonylethoxy and 3-methoxycarbonylpropoxy; when it is halo-C,.
- 4 alkoxy is, for example, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 3-fluoropropoxy and 3-chloropropoxy; when it is C 2 .
- 4 alkanoyloxy-C 2.4 alkoxy is, for example, 2-acetoxyethoxy, 2-propionyloxyethoxy, 2-butyryloxyethoxy and 3-acetoxypropoxy; when it is 2-C,. 4 alkoxyethoxy is, for example, 2-methoxyethoxy, 2-ethoxyethoxy; when it is carboxy-C M aIkoxy is, for example, carboxymethoxy, 1-carboxyethoxy, 2-carboxyethoxy and 3-carboxypropoxy; when it is C 3 . 5 alkenyloxy is, for example, allyloxy; when it is C 3 . 5 alkynyloxy is, for example, propynyloxy; when it is C,.
- 4 aIkylthio is, for example, methylthio, ethylthio or propylthio; when it is C,. 4 alkylthio is C,. 3 alkylthio; when it is C, .4 alkylsulphinyl is, for example, methylsulphinyl, ethylsulphinyl or propylsulphinyl; when it is C,. 4 alkylsulphonyl is, for example, methylsulphonyl, ethylsulphonyl or propylsulphonyl; when it is N-C,.
- 4 alkylcarbamoyl is, for example N-methylcarbamoyl, N-ethylcarbamoyl and N-propylcarbamoyl; when it is N /V-di-(C ] . 4 alkyl)-carbamoyl is, for example
- 3 alkyl)amino is, for example, dimethylamino, N-ethyl-N-methylamino, diethylamino, N-methyl-N-propylamino or dipropylamino; when it is C 2 _ 4 aIkanoylamino is, for example, acetamido, propionamido or butyramido; when it is phenyl-C, . 4 alkyl is, for example benzyl or 2-phenylethyl; when it is phenyl-C, .4 alkoxy is, for example benzyloxy; when it is -NHCOC,.
- 4 alkyl is, for example acetamido; when it is N-phthalimido-C,. 4 alkyl is, for example 2-(N-phthalimido)ethyl or 3-(N-phthalimido)propyl; when it is C 3.8 cycloalkyl is, for example, cyclopropyl, cyclopentyl or cyclohexyl; when it is C, .4 alkanoyl is, for example, acetyl or propionyl; when it is C ⁇ alkanoyloxy is, for example, acetyloxy or propionyloxy; when it is C, .4 alkanoylamino is, for example, acetamido; when it is ⁇ -(C, .4 alkyl)ureido is, for example, N-methylureido or N-ethylureido; when it is N',N -di-(C, .4 alkyl)ure
- 4 alkyl)-N-(C,. 4 aIkyI)ureido is, for example, N-methyl-N-ethylureido or N-methyl-N-methylureido; when it is N',N'-di-(C,.
- 4 alkyl)-7V-(C M alkyl)ureido is, for example, N'JV'-dimethyl-N-ethylureido, N'-methyl-N'-propyl-N-butylureido; when it is N-(C,_ 4 aIkyl)suIphamoyl is, for example, N-methylsulphamoyl or N-isopropylsulphamoyl; when it is N,N-di-(C,. 4 alkyI)sulphamoyl is, for example, N-methyl-N-ethylsulphamoyl or N,N-dipropylsulphamoyl.
- a suitable pharmaceutically acceptable salt of a pyrimidine derivative of the invention is, for example, an acid-addition salt of a pyrimidine derivative of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
- a suitable pharmaceutically acceptable salt of a pyrimidine derivative of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, mo ⁇ holine or tris-(2-hydroxyethyl)amine.
- the compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I).
- pro-drugs include in vivo hydrolysable esters of a compound of the formula (I).
- An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
- Suitable pharmaceutically acceptable esters for carboxy include C,.
- 6 alkoxym ethyl esters for example methoxymethyl
- C,_ 6 alkanoyloxymethyl esters for example pivaloyloxymethyl
- phthalidyl esters C 3.8 cycloalkoxycarbonyloxyC
- 6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl
- l,3-dioxolen-2-onylmethyl esters for example 5-methyl-l,3-dioxolen-2-onylmethyl
- C, .6 alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxy ethyl and may be formed at any carboxy group in the compounds of this invention.
- An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
- inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
- ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
- a selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.
- substituents on benzoyl include mo ⁇ holino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4- position of the benzoyl ring.
- Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereo-isomers and geometric isomers that possess CDK and/or FAK inhibitory activity.
- the invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess CDK and/or FAK inhibitory activity.
- R 1 is selected from hydrogen, C,. 6 alkyl [optionally substituted by one or two substituents independently selected from halo, amino, C M alkylamino, di-(C M alkyl)amino, hydroxy, cyano, C,. 4 alkoxy, C,. 4 alkoxycarbonyl, carbamoyl, - ⁇ HCOC,. 4 alkyl, trifluoromethyl, phenylthio, phenoxy], benzyl, C 3 _ 5 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent, or one phenyl substituent], N-phthalimido-C M alkyl, C 3 .
- any phenyl or benzyl group in R 1 is optionally substituted by up to three substituents independently selected from halo, hydroxy, nitro, amino, C,_ 3 alkylamino, di-(C,. 3 alkyl)amino, cyano, trifluoromethyl, C M alkyl [optionally substituted by 1 or 2 substituents independently selected from halo, cyano, amino, C,. 3 alkylamino, di-(C,_ 3 alkyl)amino, hydroxy and trifluoromethyl], C 3 .
- R" is selected from halo, hydroxy, nitro, amino, C,. 3 alkylamino, di-(C, .3 alkyl)amino, cyano, trifluoromethyl, C,. 3 alkyl [optionally substituted by 1 or 2 substituents independently selected from halo, cyano, amino, C,. 3 alkylamino, di-(C,.
- Q, and Q 2 are independently selected from phenyl, naphthyl, a 5- or 6-membered monocyclic moiety (linked via a ring carbon atom and containing one to three heteroatoms independently selected from nitrogen, oxygen and sulphur); and a 9- or 10-membered bicyclic heterocyclic moiety (linked via a ring carbon atom and containing one or two nitrogen heteroatoms and optionally containing a further one or two heteroatoms selected from nitrogen, oxygen and sulphur); provided that when a substituent of formula (la') (defined hereinbelow) is present in Q, there is an available carbon atom in Q, such that the substituent of formula (la') is not adjacent to the - ⁇ H- link); and one or both of Q, and Q 2 bears on any available carbon atom one substituent of the formula (la') and Q 2 may bear on any available carbon atom further substituents of the formula (la')
- X is CH 2 , O, NH or S; Y is H or as defined for Z;
- Z is OH, SH, NH 2 , C,_ 4 alkoxy, C M alkylthio, -NHC,. 4 alkyl, -N(C,_ 4 alkyl) 2 , pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, mo ⁇ holino or thiomo ⁇ holino; n is 1, 2 or 3; m is 1, 2 or 3; and Q, may optionally bear on any available carbon atom up to four substituents independently selected from halo, thio, nitro, carboxy, cyano, C 2 . 4 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C 2 .
- 4 alkyl and phenyl-C ,_ 4 alkoxy substituents may optionally bear one or two substituents independently selected from halo, C,_ 4 alkyl and C,_ 4 alkoxy; and Q 2 may optionally bear on any available carbon atom up to four substituents independently selected from halo, hydroxy, thio, nitro, carboxy, cyano, C 2 . 4 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C 2 _ 4 alkynyl, C, .5 alkanoyl, C M alkoxycarbonyl, C,_ 6 alkyl, hydroxy-C,_ 3 alkyl, fluoro-C,.
- Q 2 may optionally bear on any available carbon atom up to two further substituents independently selected from phenyl-C M alkyl, phenyl-C M alkoxy, phenyl, naphthyl, benzoyl and a 5- or 6-membered aromatic heterocycle (linked via a ring carbon atom and containing one to three heteroatoms independently selected from oxygen, sulphur and nitrogen); wherein said naphthyl, phenyl, benzoyl, 5- or 6-membered aromatic heterocyclic substituents and the phenyl group in said phenyl-C M alkyl and phenyl- C M alkoxy substituents may optionally bear one or two substituents independently selected from halo, C alkyl and C M alkoxy; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
- Particular preferred compounds of the invention comprise a pyrimidine derivative of the formula (I), or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, wherein R 1 , R x , Q crayon Q 2 , X, Y, Z, m and n have any of the meanings defined hereinbefore, or any of the following values.
- R 1 , R x , Q crayon Q 2 , X, Y, Z, m and n have any of the meanings defined hereinbefore, or any of the following values.
- Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter:- (1)
- Q, and Q 2 are selected from phenyl, pyridyl, indanyl, indazolyl, indolyl, quinolyl, pyrazolyl or thiazolyl;
- Q, and Q 2 are both phenyl or both pyridyl or Q, is phenyl and Q 2 is indanyl, pyridyl, indazolyl, indolyl, quinolyl, pyrazolyl or thiazolyl or Q, is pyridyl and Q 2 is phenyl;
- Q, and Q 2 are both phenyl or Q, is 3-pyridyl and Q, is 2-pyridyl or Q, is phenyl and Q 2 is 5-indanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, lH-5-indazolyl, 5-indolyl, 6-quinolyl, 3-pyrazolyl or 2-thiazolyl or Q, is 3-pyridyl and Q 2 is phenyl;
- Q, and Q 2 are both phenyl or Q, is phenyl and Q 2 is indanyl, pyridyl or thiazolyl;
- Q, and Q 2 are both phenyl or Q, is phenyl and Q 2 is pyridyl; (6) Q, and Q 2 are both phenyl or Q, is phenyl and Q 2 is indanyl, pyridyl or indazolyl;
- Q, and Q 2 are preferably both phenyl
- and Q 2 are selected from phenyl and pyridyl.
- Q, and Q 2 are selected from pyridyl.
- R 1 is preferably hydrogen, benzyl, C 3 _ 5 alkynyl (especially propyn-2-yl), C 3 . 6 cycloalkyl-C,. 6 alkyl (especially cyclopropylmethyl), C M alkyl [optionally substituted by one substituent selected from hydroxy, amino, halo, trifluoromethyl and cyano] or C 3 . 5 alkenyl substituted by one to three halo groups;
- R 1 is hydrogen
- R 1 is preferably benzyl, C 3 . 5 alkynyl (especially propyn-2-yl), C 3 _ 6 cycloalkyl-C ⁇ _ 6 alkyl (especially cyclopropylmethyl), C M alkyl [optionally substituted by one substituent selected from hydroxy, amino, halo, trifluoromethyl and cyano] or C 3 _ 5 alkenyl substituted by one halo group;
- R 1 is more preferably C 3 _ 5 alkynyl (especially propyn-2-yl) or C M alkyl [optionally substituted by trifluoromethyl or cyano] or C 3.5 alkenyl substituted by one bromo group;
- R x is more preferably selected from halo (especially bromo), nitro and C,_ 3 alkyl (especially methyl);
- R is selected from halo, hydroxy, nitro, amino, jalkylamino, di-(C ] _ 3 alkyl)amino, cyano, trifluoromethyl, C,. 3 alkyl [optionally substituted by 1 or 2 substituents independently selected from halo, di-(C,_ 3 alkyl)amino, hydroxy and trifluoromethyl], C 3 . 5 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C 3 . 5 alkynyl, C,_ 3 alkoxy, -SH, -S-C,_ 3 alkyl, carboxy, C M alkoxycarbonyl;
- R ⁇ is selected from halo, hydroxy, nitro, amino, cyano, mercapto, carboxy, sulphamoyl, formamido, ureido or carbamoyl or a group of formula (lb):
- A is C,_ 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C 3 _ 8 cycloalkyl, phenyl, heterocycle or heteroaryl, wherein said C M alkyl, C 3 _ 6 alkenyl and C 3 _ 6 alkynyl are optionally substituted by one or more substituents selected from halo, nitro, mercapto, formamido, ureido, di-(C,. 3 alkyl)amino, trifluoromethyl, C 3 . 8 cycloalkyl, phenyl, heterocycle or heteroaryl; wherein any phenyl, C 3 .
- cycloalkyl, heterocycle or heteroaryl may be optionally substituted by one or more halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, formamido, ureido, sulphamoyl, C M alkyl, C 2 . 4 alkenyl, C 2 . 4 alkynyl, C,. 4 alkoxy, C,. 4 alkanoyl, C M alkanoyloxy, C M alkylamino, di-(C M alkyl)amino, C,. 4 alkanoylamino, N-C,.
- B is -O-, -S-, - ⁇ H-, -N(C 1 . 4 alkyl)-, -C(O)NH-, -C(O)N(C M alkyl)-, -N(C M alkyl)C(O)- or B is a direct bond;
- C is C M alkylene or a direct bond
- R x is selected from halo, hydroxy, nitro, amino, C ⁇ _ 3 alkylamino, di-(C,_ 3 alkyl)amino, cyano, trifluoromethyl, C,. 3 alkyl [optionally substituted by 1 or 2 substituents independently selected from halo, cyano, amino, C,. 3 alkylamino, di-(C,_ 3 alkyl)amino, hydroxy and trifluoromethyl], C 3 . 5 alkenyl [optionally substituted by up to three halo substituents, or by one trifluoromethyl substituent], C 3 . 5 alkynyl, C,. 3 alkoxy, -SH, -S-C,_ 3 alkyl, carboxy;
- R is selected from halo, nitro, amino, cyano or carboxy or a group of formula (lb) (as depicted above) wherein A is C, .6 alkyl, C 2 _ 6 alkenyl, C 3 _ 8 cycloalkyl, phenyl, heterocycle or heteroaryl, wherein said C,. 6 alkyl and C 3 _ 6 alkenyl are optionally substituted by one or more substituents selected formamido, ureido, C,. 3 alkylamino, di-(C,.
- R is selected from fluoro, chloro, bromo, nitro, amino, cyano or carboxy or a group of formula (lb) (as depicted above) wherein A is methyl, isopropyl, propyl, ethyl, butyl, vinyl, allyl, cyclohexyl, phenyl, mo ⁇ holino, imidazolyl, isoxazolyl, quinolinyl, benzothienyl, pyrazolyl, thiazolyl, tetrazolyl or furyl, wherein said methyl, isopropyl, propyl, ethyl, butyl, vinyl, allyl, are optionally substituted by one or more substituents selected formamido, ureido, methylamine, dimethylamino, diethylamino, hydroxy, phenyl, cyclopentyl, or heteroaryl; wherein any phenyl or isoxazolyl may be
- R x is selected from fluoro, chloro, bromo, nitro, amino, cyano, carboxy, methyl, methoxy, ethoxy, ethoxymethyl, vinyl, allyloxymethyl, hydroxymethyl, 2-hydroxyethoxymethyl, 4-hydroxybutoxymethyl, dimethylaminomethyl, diethylaminomethyl, ureidomethyl, formamidomethyl, methylaminomethyl, isopropylaminocarbonyl, phenyl, benzyl, phenethyl, benzoylamino, 4-phenylbutyryl, 2-phenylvinyl (optionally substituted by fluoro), benzyloxymethyl, cyclohexyloxymethyl, 3-cyclopentylpropionyl, mo ⁇ holino, furyl, imidazolylmethyl, isoxazolyloxymethyl (optionally substituted by methyl), quinolinylaminomethyl, benzothienylaminomethyl, pyrazolylamino
- R x is selected from chloro, bromo, nitro, cyano and tetrazolylthiomethyl; (27) R x is selected from fluoro, chloro, bromo and cyano;
- R x is bromo
- X is O
- Y is OH and Z is -N(C M alkyl) 2 ; preferably n is i and m is 1 ;
- X is -O-, Y' is OH, Y 2 is H and Z is -N(C,. 4 alkyl) 2 ; n is 1 and m is 1 ;
- substituent of formula (la') there is one substituent of formula (la'), and this substituent is in ring Q, (i.e. a ring linked via -NH-);
- X is -O-, -NH-, -NR y - [wherein R y is C, .4 alky], Y 1 is H, C M alkyl or hydroxy, Y 2 is H or C,.
- Z is RO-, R b R c N-, R e R f NNR ⁇ a nitrogen linked heteroaryl or a nitrogen linked heterocycle [wherein said heterocycle is optionally substituted on a ring carbon or a ring nitrogen by C, .4 alkyl or C M alkanoyl] wherein R a , R b , R c , R e , R f and R are independently selected from hydrogen, C M alkyl, C 2 . 4 alkenyl, C 3 _ 8 cycloalkyl, and wherein said C,. 4 alkyl are optionally substituted by one or more phenyl, n is 1 and m is 1;
- the substituent of formula (la) is 3-dimethylaminopropoxy, 3-dimethylamino-2-hydroxypropoxy, 3-diethylaminopropoxy or 3-isopropylamino-2-hydroxypropoxy;
- substituents for Q 2 include halo, hydroxy-C ⁇ _ alkyl, fluoro-C, .4 alkyl (especially trifluoromethyl), mo ⁇ holino and C,. 4 alkyl (especially methyl);
- More preferable further substituents for Q 2 include halo, mo ⁇ holino and C,_ 4 alkyl (especially methyl); (42) Further substituents for Q 2 include halo, hydroxy, cyano, C,_ 6 alkyl, hydroxy-C ⁇ alkyl, fluoro-C alkyl, C 1 . 4 alkoxy-C,_ 3 alkyl, mo ⁇ holino, C M alkoxy, 2-mo ⁇ holino-ethoxy, 2-imidazo-l-yl-ethoxy, C,. 4 alkylthio, carbamoyl, amino, C 2 _ 4 alkanoylamino, sulphamoyl, phenyl-C ,.
- a further substituent for Q 2 is methyl
- Q is unsubstituted or substituted by methyl;
- Further substituents for Q 2 include fluoro, chloro, bromo, cyano, methyl, hydroxymethyl, methoxy;
- the ring Q, or Q, not bearing the substituent of formula (la') is substituted by one or two further substituents, preferably halo, mo ⁇ holino and/or C alkyl (especially methyl);
- the ring Q bears the substituent of formula (la') and Q 2 is substituted by one or two further substituents, selected preferably from halo, hydroxy-C,_ 3 alkyl, fluoro-C,. 4 alkyl (especially trifluoromethyl), mo ⁇ holino and C M alkyl (especially methyl);
- a further substituent for Q, is halo
- a further substituent for Q is fluoro
- a preferred compound of the invention is a pyrimidine derivative of the formula (I), or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, wherein:
- Qi and Q 2 are both phenyl
- R is bromo, nitro or methyl (especially bromo or nitro);
- Q bears one substituent of formula (la') (especially 3-dimethylamino-2-hydroxypropoxy), preferably in the para-position; and
- Q 2 bears one or two substituents independently selected from halo, mo ⁇ holino and C M alkyl
- a preferred compound of the invention is a pyrimidine derivative of the formula (I), or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, wherein:
- Qi and Q 2 are both phenyl or both pyridyl or Q, is phenyl and Q 2 is indanyl, pyridyl, indazolyl, indolyl, quinolyl, pyrazolyl or thiazolyl or Q, is pyridyl and Q, is phenyl;
- R ⁇ is fluoro, chloro, bromo, nitro, amino, cyano, carboxy, methyl, methoxy, ethoxy, ethoxymethyl, vinyl, allyloxymethyl, hydroxymethyl, 2 -hydroxy ethoxymethyl, 4-hydroxybutoxymethyl, dimethylaminomethyl, diethylaminomethyl, ureidomethyl, formamidomethyl, methylaminomethyl, isopropylaminocarbonyl,
- Q is optionally substituted by fluoro and is substituted by a group of formula (la) which is 3-amino-2-hydroxypropoxy, 3-methylamino-2-hydroxypropoxy, 3 -dimethylaminopropoxy, 3 -dimethylamino-2-hydroxypropoxy, 3-ethylamino-2-hydroxypropoxy, 3-diethylaminopropoxy, 3-isopropylaminopropoxy, 3-isopropylamino-2-hydroxypropoxy, 3-isopropylamino-2-hydroxy-2-methylpropoxy, 3-isobutylamino-2-hydroxypropoxy, 3-t-butylamino-2-hydroxypropoxy, 3-ethoxy-2-hydroxypropoxy, 3-(N-isopropyl-N-benzylamino)-2-hydroxypropoxy, 3-(N-allyl-N-methylamino)-2-hydroxypropoxy, 3-(4-methylpiperazin- 1 -yl)propoxy, 3 -(4-methylpiperazin- 1 -yl
- Q 2 is optionally substituted by one or two halo, hydroxy, cyano, C,. 6 alkyl, hydroxy-C,_ 3 alkyl, fluoro-C M alkyl, C,. 4 alkoxy-C,. 3 alkyl, mo ⁇ holino, C,. 4 alkoxy, 2-mo ⁇ holino-ethoxy, 2-imidazo-l-yl-ethoxy, C,. 4 alkylthio, carbamoyl, amino, C 2.4 alkanoylamino, sulphamoyl, phenyl-C M alkyl, phenyl-C,. 4 alkoxy, phenyl and phenoxy.
- a preferred compound of the invention is a pyrimidine derivative of the formula (I), or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, wherein:
- Q, and Q 2 are both phenyl or Q, is phenyl and Q 2 is indanyl, pyridyl or thiazolyl;
- R' is hydrogen
- R ⁇ is selected from chloro, bromo, nitro, cyano and tetrazolylthiomethyl
- Q is substituted by a group of formula (la) which is 3-dimethylamino-2-hydroxypropoxy, 3-isopropylaminopropoxy,
- a preferred compound of the invention is a pyrimidine derivative of the formula (I), or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, wherein:
- Q, and Q 2 are both phenyl or Q, is phenyl and Q 2 is indanyl, pyridyl or indazolyl;
- R' is hydrogen or -CH 2 CH 2 CH 2 CF 3 ;
- R x is selected from fluoro, chloro, bromo and cyano;
- Q is substituted by a group of formula (la) which is 3-dimethylaminopropoxy, 3-dimethylamino-2-hydroxypropoxy, 3-diethylaminopropoxy or 3-isopropylamino-2-hydroxypropoxy; and
- Q 2 is optionally substituted by one or two fluoro, bromo, methyl, hydroxymethyl, methoxy, 2-imidazo- 1 -ylethoxy and phenyl.
- a specific preferred compound of the invention is the following pyrimidine derivative of the formula (I): -
- preferred compounds of the invention are those of Examples 3, 118, 151, 188, 218, 234 or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
- preferred compounds of the invention are those of
- Examples 47 or 111 or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof are preferred compounds of the invention.
- preferred compounds of the invention include any one of the Examples or pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.
- Preferred aspects of the invention are those which relate to the compound or a pharmaceutically acceptable salt thereof.
- a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof may be prepared by any process known to be applicable to the preparation of chemically-related compounds. Such processes, when used to prepare a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, are provided as a further feature of the invention and are illustrated by the following representative examples in which, unless otherwise stated R 1 , Q,, Q 2 , R x , X, Y 1 , Y 2 , Z, m and n have any of the meanings defined hereinbefore for a pyrimidine derivative of the formula (I) and unless another substituent is drawn on ring Q, or Q 2 the ring may bear any of the substituents described hereinbefore (optionally protected as necessary).
- A is O, S or NH; with a nucleophile of formula (VII):
- L is a displaceable group
- suitable values for L are for example, a halo or sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.
- Alternative suitable groups for L include halo, mesyl, methylthio and methylsulphinyl.
- D is hydrogen or a counter-ion.
- suitable values for D include sodium and potassium.
- LgO is a leaving group. Suitable values for LgO include mesylate and tosylate.
- Pyrimidines of formula (II) and anilines of formula (III) may be reacted together: i) optionally in the presence of a suitable acid, for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid.
- a suitable acid for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid.
- the reaction is preferably carried out in a suitable inert solvent or diluent, for example dichloromethane (DCM), acetonitrile, butanol, tetramethylene sulphone, tetrahydrofuran, 1,2-dimethoxyethane, N,N-dimethylformamide, NJV-dimethylacetamide or N-methylpyrrolidin-2-one, and at a temperature in the range, for example, 0°to 150°C, conveniently at or near reflux temperature; or ii) under standard Buchwald conditions (for example see J. Am. Chem. Soc, 118, 7215; J. Am. Chem. Soc, 119, 8451; J. Org.
- a suitable inert solvent or diluent for example dichloromethane (DCM), acetonitrile, butanol, tetramethylene sulphone, tetrahydrofuran, 1,2-dimethoxyethane, N
- Chem., 62, 1568 and 6066 for example in the presence of palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-t-butoxide, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-l,l'-binaphthyl and at a temperature in the range of 25 to 80°C.
- a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene
- a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-t-butoxide
- a suitable ligand such as 2,2'-bis(diphenylphosphino)-l,l'-binaphthyl and at a temperature in the range of 25 to 80
- R a is an optionally substituted alkyl or aryl group and L is a displaceable group as defined above.
- R a is methyl, ethyl or p-tolyl.
- Pyrimidines of formula (IV) and anilines of formula (V) may be reacted together, i) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or N-methyl pyrrolidine, optionally in the presence of a suitable acid such as those defined above (or a suitable Lewis acid) and at a temperature in the range of 0°C to reflux, preferably reflux; or ii) under standard Buchwald conditions as described above.
- a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or N-methyl pyrrolidine
- a suitable acid such as those defined above (or a suitable Lewis acid) and at a temperature in the range of 0°C to reflux, preferably reflux; or ii) under standard Buchwald conditions as described above.
- Pyrimidines of formula (IV) are prepared according to the following scheme: (IV) wherein L is a displaceable group as defined above and R 1 is not hydrogen.
- the anilines of formula (V) are commercially available or are prepared by processes known in the art.
- Pyrimidines of the formula (IVA) are commercially available or may be prepared by, for example, reacting a compound of formula (IVA) in which L is -OH (i.e. a uracil), with POCl 3 to give a compound of formula (IVA) in which L is -Cl.
- Three membered heteroalkyl rings of formula (VI) and nucleophiles of formula (VII) are reacted together at a temperature in the range of 20° to 100°C, preferably 20° to 50°C, optionally in the presence of a suitable solvent, for example N,N-dimethylformamide, dimethyl sulphoxide or tetrahydrofuran.
- a suitable solvent for example N,N-dimethylformamide, dimethyl sulphoxide or tetrahydrofuran.
- Alcohols (e.g. phenols) of formula (VIII) and alcohols of formula (IX) can be reacted together under standard Mitsunobu conditions.
- a suitable solvent such as dichloromethane, toluene or tetrahydrofuran
- alcohols (phenols) of formula (VIII) may be alkylated with a suitable compound of formula (IX) in which the terminal hydroxy group has been replaced by a suitable leaving group.
- Alcohols of formula (VIII) are made according to the process in I) above for the synthesis of intermediate (VIB) (where X is oxygen).
- Alcohols of formula (IX) are commercially available or are made by processes known in the art.
- compounds in which X is -S- may be prepared by reaction of a compound of formula (VIII) in which the hydroxy group is -SH, with a compound of formula (IX) in which the hydroxy group is a leaving group such as mesylate or to sy late.
- steps 1) and 2) in the final step may be reversed.
- a suitable base for step 2) is triethylamine.
- Suitable starting materials containing a thioacetate group are prepared from corresponding compounds containing a leaving group such as mesylate or tosylate (prepared using standard conditions from the corresponding hydroxy compound) using thiol acetic acid as described herein for the conversion of compounds of formula (IG) into (IJ).
- Examples of conversions of a compound of formula (I) into another compound of formula (I) are: i) conversion of R 1 as hydrogen into other R' for example:
- Ms is methanesulphonyl
- Nu is a nucleophile that introduces a substituent that is an optional substituent for R 1 as defined in formula (I), such as Nu is -NH,, -NHC,. 4 alkyl, -N(C,. 4 alkyl) 2 or -CN (NB the hydroxyl moiety does not necessarily have to be on the terminal carbon as depicted above); iii) conversion of one side chain of formula (la) into another side chain of formula (la), for example:
- a preferred process of the invention is Process b).
- aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halo group.
- modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkyl sulphonyl.
- a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
- the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
- a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
- a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
- the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- an arylmefhyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
- the pyrimidine derivative defined in the present invention possesses anti-cell-proliferation activity such as anti-cancer activity which is believed to arise from the CDK and/or FAK inhibitory activity of the compound. These properties may be assessed, for example, using the procedure set out below :-
- HEPES is N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
- DTT is Dithiothretiol
- PMSF Phenylmethylsulfonyl fluoride
- the plates were sealed with Topseal-S plate sealers, left for two hours then spun at 2500 ⁇ m, 1124xg., for 5 minutes. The plates were read on a Topcount for 30 seconds per well.
- the incubation buffer used to dilute the enzyme and substrate mixes contained 50mM HEPES pH7.5, lOmM MnCl 2 , ImM DTT, lOO ⁇ M Sodium vanadate, lOO ⁇ M NaF, lOmM Sodium Glycerophosphate, BSA (lmg/ml final).
- test substrate As a control, another known inhibitor of CDK4 may be used in place of pi 6.
- Test substrate As a control, another known inhibitor of CDK4 may be used in place of pi 6.
- the retinoblastoma 792-928 sequence so obtained was expressed in E.Coli (BL21 (DE3) pLysS cells ) using standard inducible expression techniques, and purified as follows.
- E.coli paste was resuspended in lOml/g of NETN buffer (50mM Tris pH 7.5, 120mM NaCl, ImM EDTA, 0.5%v/v NP-40, ImM PMSF, lug/ml leupeptin, lug/ml aprotinin and lug/ml pepstatin) and sonicated for 2 x 45 seconds per 100ml homogenate. After centrifugation, the supernatant was loaded onto a 10ml glutathione Sepharose column (Pharmacia Biotech, Herts, UK), and washed with NETN buffer.
- NETN buffer 50mM Tris pH 7.5, 120mM NaCl, ImM EDTA, 0.5%v/v NP-40, ImM PMSF, lug/ml leupeptin, lug/ml aprotinin and lug/ml pepstatin
- kinase buffer 50mM HEPES pH 7.5, lOmM MgC12, ImM DTT, imM PMSF, lug/ml leupeptin, lug/ml aprotinin and lug/ml pepstatin
- the protein was eluted with 50mM reduced glutathione in kinase buffer.
- Fractions containing GST-Rb(792-927) were pooled and dialysed overnight against kinase buffer. The final product was analysed by Sodium Dodeca Sulfate (SDS) PAGE (Polyacrylamide gel) using 8-16% Tris-Glycine gels (Novex, San Diego, USA).
- SDS Sodium Dodeca Sulfate
- CDK4 and Cyclin Dl were cloned from RNA from MCF-7 cell line (obtained from ATCC number:HTB22, breast adenocarcinoma line) as follows.
- the RNA was prepared from MCF-7 cells, then reverse transcribed using oligo dT primers.
- PCR was used to amplify the complete coding sequence of each gene [CDK4 amino acids 1-303; Refi Cell 1992 Oct 16; 71(2): 323-334; Matsushime H., Ewen M.E., Stron D.K., Kato J.Y., Hanks S.K., Roussel M.F., Sherr C.J. and Cyclin Dl amino acids 1-296; Ref. Cold Spring Harb. Symp. Quant. BioL, 1991 ; 56:93-97; Arnold A., Motokura T., Bloom T., Kronenburg, Rudemian J., Juppner H., Kim H.G.].
- PCR products were cloned using standard techniques into the insect expression vector pVL1393 (obtained from Invitrogen 1995 catalogue number : VI 392-20). The PCR products were then dually expressed [using a standard virus Baculogold co-infection technique] into the insect SF21 cell system (Spodoptera Frugiperda cells derived from ovarian tissue of the Fall Army Worm -Commercially available).
- Example production of Cyclin D1/CDK4 provides details of the production of Cyclin D1/CDK4 in SF21 cells (in TCI 00 + 10% FBS(TCS) + 0.2% Pluronic) having dual infection MOI 3 for each virus of Cyclin Dl & CDK4.
- Example production of Cyclin D1/CDK4 provides details of the production of Cyclin D1/CDK4 in SF21 cells (in TCI 00 + 10% FBS(TCS) + 0.2% Pluronic) having dual infection MOI 3 for each virus of Cyclin Dl & CDK4.
- SF21 cells grown in a roller bottle culture to 2.33 x 10 6 cells/ml were used to inoculate 10 x 500 ml roller bottles at 0.2 x 10E6 cells/ml.
- the roller bottles were incubated on a roller rig at 28°C.
- the mixture was spun down, the supernatant added to nickel chelate beads and mixed for 1 l A hours.
- the beads were washed in sodium phosphate, NaCl pH 6.0 and pl6 product eluted in sodium phosphate, NaCl pH 7.4 with 200mM imidazole.
- the pTB NBSE was constructed from pTB 375 NBPE as follows :- p TB375
- pTB375 was generated by the addition of an expression cassette consisting of the T7 gene 10 promoter, multiple cloning site and T7 gene 10 termination sequence. In addition, a terminator sequence designed to reduce transcriptional readthrough from the background vector was included upstream of the expression cassette.
- a new multiple cloning site containing the recognition sequences for the restriction enzymes Ndel, BamHI, Smal and EcoRI was introduced into pTB 375 NBPE between the Ndel and EcoRI sites.
- the oligonucleotide containing these restriction sites also contained 6 histidine codons located between the Ndel and BamHI sites in the same reading frame as the inititiator codon (ATG) present within the Ndel site.
- CDK2 EMBL Accession No. X62071
- Cyclin A or Cyclin E see EMBL Accession No. M73812
- PCT International Publication No. WO99/21845 the relevant Biochemical & Biological Evaluation sections of which are hereby inco ⁇ orated by reference.
- CDK2 with Cyclin E partial co-purification may be achieved as follows:- Sf21 cells are resuspended in lysis buffer (50mM Tris pH 8.2, lOmM MgCl 2 , ImM DTT, lOmM glycerophosphate, O.lmM sodium orthovanadate, O.lmM NaF, ImM PMSF, lug/ml leupeptin and lug/ml aprotinin) and homogenised for 2 minutes in a 10ml Dounce homgeniser. After centrifugation, the supernatant is loaded onto a Poros HQ/M 1.4/100 anion exchange column (PE Biosystems, Hertford, UK).
- lysis buffer 50mM Tris pH 8.2, lOmM MgCl 2 , ImM DTT, lOmM glycerophosphate, O.lmM sodium orthovanadate, O.lmM NaF, ImM PMSF, lug/ml le
- CDK2 and Cyclin E are coeluted at the beginning of a 0-1 M NaCl gradient (run in lysis buffer minus protease inhibitors) over 20 column volumes. Co-elution is checked by western blot using both anti-CDK2 and anti-Cyclin E antibodies (Santa Cruz Biotechnology, California, US).
- FAK3 Kinase Inhibition Assay This assay determines the ability of a test compound to inhibit tyrosine kinase activity of human Focal Adhesion Kinase (FAK).
- DNA encoding FAK is obtained by total gene synthesis (Edwards M, International Biotechnology Lab 5(3), 19-25, 1987) or by cloning. These are then expressed in a suitable expression system to obtain polypeptide with tyrosine kinase activity.
- FAK obtained by expression of recombinant protein in insect cells, was found to display intrinsic tyrosine kinase activity.
- FAK full length human cDNA described by Andre et al (Biochemical and Biophysical Research Communications, 1993, 190 (1): 140-147; EMBL/GenBank Accession Number L05186)
- FAK full length human cDNA described by Andre et al (Biochemical and Biophysical Research Communications, 1993, 190 (1): 140-147; EMBL/GenBank Accession Number L05186)
- Active FAK protein has been previously expressed in a baculovirus system using a similar N-terminal 6-histidine tag (Protein Expression And Purification, 1996, 7: 12-18).
- the human FAK cDNA was cloned into the baculovirus transplacement vector, pFastbac 1 (Life Technologies), and the recombinant construct was co-transfected into insect cells (for example Spodoptera frugiperda 21(Sf21)) with viral DNA to prepare recombinant baculovirus (details of the methods for the assembly of recombinant DNA molecules and the preparation and use of recombinant baculovirus can be found in standard texts for example Sambrook et al, 1989, Molecular cloning - A Laboratory Manual, 2nd edition, Cold Spring Harbour Laboratory Press and O'Reilly et al, 1992, Baculovirus Expression Vectors - A Laboratory Manual, W. H. Freeman and Co, New York. Details specific to the use of the pFastbac ('Bac to Bac') system are provided in Anderson et al., 1995, FOCUS (Life Technologies Bulletin Magazine), 17, p53.)
- a stock of substrate solution was prepared from a random copolymer containing tyrosine, for example Poly (Glu, Ala, Tyr) 6:3:1 (Sigma P3899), stored as 1 mg/ml stock in PBS at -20°C and diluted 1 in 500 with PBS for plate coating.
- Poly (Glu, Ala, Tyr) 6:3:1 Sigma P3899
- Test compounds were made up as lOmM or 30mM stocks in DMSO and then further diluted in glass distilled water diluted to a concentration 10 fold higher than the final assay concentration. lO ⁇ l of diluted compound was transferred to wells in the washed assay plates. "No compound" control wells contained lOul glass distilled water instead of compound.
- the in- vivo activity of the compounds of the present invention may be assessed by standard techniques, for example by measuring inhibition of cell growth and assessing cytotoxicity.
- Inhibition of cell growth may be measured by staining cells with Sulforhodamine B (SRB), a fluorescent dye that stains proteins and therefore gives an estimation of amount of protein (i.e. cells) in a well (see Boyd, M. R. (1989) Status of the NCI preclinical antitumour drug discovery screen. Prin. Prac Oncol 10:1-12). Thus, the following details are provided of measuring inhibition of cell growth:-
- SRB Sulforhodamine B
- Cells were plated in appropriate medium in a volume of lOO ⁇ l in 96 well plates; media was Dulbecco's Modified Eagle media for MCF-7, SK-UT-1B and SK-UT-1. The cells were allowed to attach overnight, then inhibitor compounds were added at various concentrations in a maximum concentration of 1% DMSO (v/v). A control plate was assayed to give a value for cells before dosing. Cells were incubated at 37°C, (5% CO2) for three days.
- the SRB bound to protein was solubilised in lOmM Tris pH7.5 and shaken for 30 minutes at room temperature.
- the ODs were read at 540nm, and the concentration of inhibitor causing
- Typical IC 50 values for compounds of the invention when tested in the SRB assay are in the range ImM to InM.
- a pharmaceutical composition which comprises a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in association with a pharmaceutically acceptable diluent or carrier.
- composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
- sterile solution emulsion
- topical administration as an ointment or cream or for rectal administration as a suppository.
- compositions may be prepared in a conventional manner using conventional excipients.
- the pyrimidine will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose.
- a unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
- Preferably a daily dose in the range of 1-50 mg/kg is employed.
- the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- the pyrimidine derivatives defined in the present invention are effective cell cycle inhibitors (anti-cell proliferation agents), which property (without being bound by theory) is believed to arise from their (Gl-S phase) CDK inhibitory properties.
- the compounds are also effective inhibitors of FAK. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by CDK and/or FAK enzymes, i.e. the compounds may be used to produce a CDK and/or FAK inhibitory effect in a warm-blooded animal in need of such treatment.
- the compounds of the present invention provide a method for treating the proliferation and/or migration of malignant cells characterised by inhibition of CDK and/or FAK enzymes, i.e. the compounds may be used to produce an anti-proliferative/migration effect mediated alone or in part by the inhibition of CDKs and/or FAK.
- the compounds may also be useful as FAK inhibitors by inducing cell-death (apoptosis).
- a pyrimidine derivative of the invention is expected to possess a wide range of anti-cancer properties as CDKs and/or FAK have been implicated in many common human cancers such as leukaemia and breast, lung, colon, rectal, stomach, prostate, bladder, pancreas and ovarian cancer.
- a pyrimidine derivative of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a pyrimidine derivative of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, prostate and pancreas. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin.
- Such compounds of the invention are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with CDK and/or FAK, especially those tumours which are significantly dependent on CDK and/or FAK for their growth and spread, including for example, certain tumours of the colon, breast, prostate, lung, vulva and skin.
- a pyrimidine derivative of the present invention will possess activity against other cell-proliferation/migration diseases in a wide range of other disease states including leukemias, fibroprohferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.
- a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore for use as a medicament and the use of a pyrimidine derivative of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of an anti-cancer, cell cycle inhibitory (anti-cell-proliferation) effect and/or a FAK inhibitory (anti-cell migration and/or apoptosis inducing) effect in a warm-blooded animal such as man.
- a cell cycle inhibitory effect is produced at the Gl-S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK4 and CDK6.
- a method for producing an anti-cancer, cell cycle inhibitory (anti-cell-proliferation) effect and/or a FAK inhibitory (anti-cell migration and/or apoptosis inducing) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a pyrimidine derivative as defined immediately above.
- an inhibitory effect is produced at the Gl-S phase by inhibition of CDK2, CDK4 and/or CDK6, especially CDK4 and CDK6.
- the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
- a unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.
- the CDK and/or FAK inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments.
- Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
- the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy.
- Such chemotherapy may cover three main categories of therapeutic agent:
- cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrazole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 ⁇ -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function, (such growth factors include for example
- a pharmaceutical product comprising a pyrimidine derivative of the formula (I) as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.
- An anti-emetic may also be usefully administered, for example when using such conjoint treatment as described above.
- the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- fur-3-yl 2.8 (m, 6H), 3.1-3.3 (m, 2H), 3.9 (m, 2H), 4.3 (m, IH), 6.8 446 (s, IH), 6.85 (d, 2H), 7.2 (t, IH), 7.3-7.4 (m, 4H), 7.5 (d, 2H), 7.8 (s, IH), 8.1 (s, 2H), 9.4 (s, IH), 10.0 (br s, IH), 10.5-10.6 (br s, IH)
- a sample of the di-hydrochloride salt of this example was also prepared.
- the free base (165 mg, 0.38 mmol) was dissolved in ethyl acetate/diethyl ether (1 :3 v/v, 5 ml).
- Ethereal hydrogen chloride (1.0M; 1.2 ml, 1.2 mmol) was added.
- the precipitated solid was collected by filtration and washed with diethyl ether, giving the dihydrochloride salt as a hygroscopic solid (150 mg).
- Example 86 The following compounds were prepared in by an analogous method to that described in Example 88, using 4-anilino-5-(ethoxymethyl)-2- ⁇ 4-[2-hydroxy-3-(N,N-dimethylamino) propoxy] anilino ⁇ pyrimidine (Example 86) and the appropriate alcohol.
- Example 86 The following compounds were prepared by an analogous method to that described in Example 93 using 4-anilino-5-(ethoxymethyl)-2- ⁇ 4-[2-hydroxy-3-N,N-dimethylamino) propoxy] anilino ⁇ pyrimidine (Example 86) and the appropriate heterocycle.
- Example 86 The following compounds were prepared by an analogous method to that described in Example 93, using 4-anilino-5-(ethoxymethyl)-2- ⁇ 4-[2-hydroxy-3-N,N-dimethylamino) propoxy] anilino ⁇ pyrimidine (Example 86) and the appropriate amine hydrochloride salt.
- Racemic 4-anilino-5-bromo-2- ⁇ 4-[3-(N,N-dimethyl)amino-2-hydroxypropoxy]anilino ⁇ pyrimidine (Example 3; 200 mg) was applied to a Chiralcel OJ column (Daicel Technologies Ltd; 250 cm x 2 cm), mobile phase iso-hexane/isopropanol/triethylamine (60:40:0.1, flow rate 9 ml/min). The resolved enantiomers were isolated and the solvent was removed.
- Enantiomeric purities were determined using a Chiralcel OJ column (250 mm x 4.6 mm), mobile phase isohexane/isopropanol/triethylamine (70:30:0.1, flow 1 ml/min, wavelength 254 nm).
- First eluted enantiomer (66 mg): retention time 23.27 minutes (analytical), 35 minutes (preparative).
- Second eluted enantiomer (67 mg): retention time 28.85 minutes (analytical), 43 minutes (preparative).
- Example 136 using 4-[2-hydroxy-3-(isopropylamino)propoxy]aniline (Pharmazie 1980, 35, 278) and the appropriate 2-chloro-5-halo-4-(2-pyridylamino)pyrimidine (Methods 81-84).
- Triphenylphosphine 400 mg, 1.5 mmol was added to a stirred solution of 4-anilino- 5-bromo-2-(4-hydroxyanilino)pyrimidine (Method 4, 178 mg, 0.5 mmol) in DCM (40 ml) and 5 the solution was stirred for 30 minutes.
- a solution of 4-(3-hydroxypropyl)m ⁇ holine 80 mg, 1.5 mmol) in DCM (2 ml) was added and the solution was stirred for 2 minutes.
- Diethyl azodicarboxylate (0.25 ml, 1.5 mmol) was added dropwise and the mixture was stirred for 20 hours. Volatile material was removed by evaporation and the residue was dissolved into ethyl acetate (100 ml). The solution was washed with water (2 x 50 ml) and then extracted with 2M
- Example 1 starting from the appropriate 5-bromo-2-chloro-4-(2-pyridylamino)pyrimidine and the appropriate 4-substituted aniline.
- the starting materials for the Examples above are either commercially available or are readily prepared by standard methods from known materials. For example, the following reactions are an illustration, but not a limitation, of some of the starting materials used in the above reactions.
- Methods 5-6 The following intermediates were prepared by an analogous method to that described in Method 4, using the appropriate aminophenol.
- Triethylsilane (0.14 ml, 1.10 mmol) was added to a solution of 4-anilino-2-chloro-5- [1 -hydroxy- l-phenylmethyl]pyrimi dine (Method 58; 170 mg, 0.55 mmol) in trifluoroacetic acid (1.5 ml), and the mixture was stirred for 64 hours.
- Water (20 ml) was added and the mixture was neutralised with sodium carbonate powder and extracted with DCM (3 x 20 ml). The extracts were combined, washed with water (30 ml), dried, concentrated to a volume of 5 ml, and loaded on a Varian Mega Bond Elut column.
- Phenylboronic acid (240 mg, 2 mmol) and tetrakis(triphenylphosphine)palladium(0) (30 mg) were added to a solution of 4-anilino-2-chloro-5-iodopyrimidine (Method 59, 331 mg, 1 mmol) in toluene (10 ml) and ethanol (2.5 ml). 2M aqueous sodium carbonate solution (10 ml) was added and the mixture was stirred and heated under reflux for 3 hours.
- N-Methylpiperazine (8.50 ml, 51.2 mmol) was added to a solution of 4-(2,3- epoxypropoxy)nitrobenzene (obtained as described in Synthetic Communications, 1.00 g, 5.12 mmol) in THF (1 ml). The solution was heated under reflux for 3 hours and then concentrated on a rotary evaporator under high vacuum at 50°C for 1 hour. The residue was dissolved in methanol (5 ml) and 10% palladium on carbon (0.50 g) and ammonium formate (3.23 g, 51.2 mmol) were added. The reaction mixture was heated under reflux for 3 hours and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to give the product as dark brown oil (1.35 g, 100%), which was used without further purification. MS (MH + ): 266.5.
- Potassium carbonate (1.0 g, 5.0 mmol) was added to a solution of 4-(3-bromopropoxy) nitrobenzene (obtained as described in Synthesis, 1990, 1069; 1.0 g, 3.9 mmol) in DMF (30 ml).
- Isopropylamine (0.4 ml, 4.6 mmol) was added and the mixture was heated at 60°C for 2 hours. Volatile material was removed by evaporation and the residue was dissolved in ethyl acetate (200 ml). The solution was washed with water (3 x 25ml) and saturated sodium chloride (25 ml) and then dried.
- N,N-Dimethylpropane-l,3-diamine (4.90 ml, 39 mmol) and potassium carbonate (6.37 g, 46 mmol) were added to l-fluoro-4-nitrobenzene (5.0 g, 35 mmol) and the mixture was heated at 70°C for 3 hours. Insoluble material was removed by filtration and the filtrate was concentrated. The residue was dissolved in ethyl acetate (100 ml) and the solution was washed with water (3 x 100ml) and saturated sodium chloride (100 ml) and dried. The solvent was removed by evaporation to give the product as a yellow oil (8.57 g). MS (MH + ): 248.
- the above formulations may be obtained by conventional procedures well known in the phanriaceutical art.
- the tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT99962375T ATE277020T1 (en) | 1998-12-24 | 1999-12-20 | PYRIMIDINE COMPOUNDS |
JP2000591012A JP2002533446A (en) | 1998-12-24 | 1999-12-20 | Pyrimidine compounds |
DE69920509T DE69920509T2 (en) | 1998-12-24 | 1999-12-20 | PYRIMIDINE COMPOUNDS |
CA002352896A CA2352896A1 (en) | 1998-12-24 | 1999-12-20 | Pyrimidine compounds |
BR9916590-2A BR9916590A (en) | 1998-12-24 | 1999-12-20 | Pyrimidine derivative, process for preparing a pyrimidine derivative, method for producing an anti-cancer effect in a warm-blooded animal, use of the pyrimidine derivative, and pharmaceutical composition |
EP99962375A EP1140860B1 (en) | 1998-12-24 | 1999-12-20 | Pyrimidine compounds |
US09/868,602 US6593326B1 (en) | 1998-12-24 | 1999-12-20 | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
NZ512118A NZ512118A (en) | 1998-12-24 | 1999-12-20 | Pyrimidine compounds useful as anticancer agents |
AU18743/00A AU763091B2 (en) | 1998-12-24 | 1999-12-20 | Pyrimidine compounds |
IL14380699A IL143806A0 (en) | 1998-12-24 | 1999-12-20 | Pyrimidine compounds |
IL143806A IL143806A (en) | 1998-12-24 | 2001-06-17 | Pyrimidine derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for the production of an anti- cancer effect in a warm-blooded animal |
NO20013038A NO319815B1 (en) | 1998-12-24 | 2001-06-19 | Pyrimidine derivative, process for the preparation and use thereof, and pharmaceutical composition. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9828511.7A GB9828511D0 (en) | 1998-12-24 | 1998-12-24 | Chemical compounds |
GB9828511.7 | 1998-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000039101A1 true WO2000039101A1 (en) | 2000-07-06 |
Family
ID=10844944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/004325 WO2000039101A1 (en) | 1998-12-24 | 1999-12-20 | Pyrimidine compounds |
Country Status (19)
Country | Link |
---|---|
US (1) | US6593326B1 (en) |
EP (1) | EP1140860B1 (en) |
JP (1) | JP2002533446A (en) |
KR (1) | KR100663773B1 (en) |
CN (1) | CN1285580C (en) |
AT (1) | ATE277020T1 (en) |
AU (1) | AU763091B2 (en) |
BR (1) | BR9916590A (en) |
CA (1) | CA2352896A1 (en) |
DE (1) | DE69920509T2 (en) |
DK (1) | DK1140860T3 (en) |
ES (1) | ES2228145T3 (en) |
GB (1) | GB9828511D0 (en) |
IL (2) | IL143806A0 (en) |
NO (1) | NO319815B1 (en) |
NZ (1) | NZ512118A (en) |
PT (1) | PT1140860E (en) |
WO (1) | WO2000039101A1 (en) |
ZA (1) | ZA200104413B (en) |
Cited By (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064656A1 (en) | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
WO2001064654A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | Pyrimidine compounds |
WO2001064655A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
WO2001072717A1 (en) * | 2000-03-28 | 2001-10-04 | Astrazeneca Ab | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
WO2002004429A1 (en) * | 2000-07-11 | 2002-01-17 | Astrazeneca Ab | Pyrimidine derivatives |
WO2001085700A3 (en) * | 2000-05-08 | 2002-02-07 | Janssen Pharmaceutica Nv | Hiv replication inhibiting pyrimidines and triazines |
WO2002022603A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002045652A2 (en) * | 2000-12-04 | 2002-06-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2002050065A2 (en) * | 2000-12-21 | 2002-06-27 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002059110A1 (en) * | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
WO2002079193A1 (en) * | 2001-03-29 | 2002-10-10 | Cyclacel Limited | Inhibitors of cyclin dependent kinases as anti-cancer agent |
WO2002096887A1 (en) * | 2001-05-30 | 2002-12-05 | Astrazeneca Ab | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
WO2002096888A1 (en) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
DE10127581A1 (en) * | 2001-05-29 | 2003-01-02 | Schering Ag | New 2-anilino-pyrimidine derivatives, are potent cyclin dependent kinase inhibitors, useful e.g. for treating cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
WO2003018022A1 (en) * | 2001-08-22 | 2003-03-06 | Amgen Inc. | 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer |
WO2003026666A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
WO2003032997A1 (en) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
WO2003048133A1 (en) * | 2001-12-07 | 2003-06-12 | Astrazeneca Ab | Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) |
US6596746B1 (en) | 1999-04-15 | 2003-07-22 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
WO2003062227A1 (en) * | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
WO2003066601A1 (en) * | 2002-02-08 | 2003-08-14 | Smithkline Beecham Corporation | Pyrimidine compounds |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2003076437A1 (en) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
WO2003078404A1 (en) * | 2002-03-15 | 2003-09-25 | Novartis Ag | Pyrimidine derivatives |
DE10212100A1 (en) * | 2002-03-11 | 2003-10-23 | Schering Ag | New 2-aminopyrimidine derivatives are cyclin-dependent kinase inhibitors useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases or viral infections |
WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2003106451A1 (en) * | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
US6670368B1 (en) | 1999-04-06 | 2003-12-30 | Astrazeneca Ab | Pyrimidine compounds with pharmaceutical activity |
WO2004014382A1 (en) * | 2002-07-29 | 2004-02-19 | Rigel Pharmaceuticals | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US6706717B2 (en) | 2000-12-21 | 2004-03-16 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
US6710052B2 (en) | 2000-03-01 | 2004-03-23 | Astrazeneca | Pyrimidine compounds |
WO2004026881A1 (en) * | 2002-08-21 | 2004-04-01 | Schering Aktiengesellschaft | Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
WO2004056786A2 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivates for the treatment of abnormal cell growth |
WO2004056807A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2004074244A2 (en) * | 2003-02-20 | 2004-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
WO2004080980A1 (en) * | 2003-03-14 | 2004-09-23 | Novartis Ag | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
US6822384B2 (en) | 2000-08-17 | 2004-11-23 | Lumera Corporation | Design and synthesis of advanced NLO materials for electro-optic applicators |
JP2004535447A (en) * | 2001-06-26 | 2004-11-25 | ブリストル−マイヤーズ スクイブ カンパニー | N-heterocyclic inhibitors of TNF-α expression |
US6844341B2 (en) | 2001-02-17 | 2005-01-18 | Astrazeneca Ab | Pyrimidine derivatives for inhibition of cell proliferation |
WO2005009443A1 (en) * | 2003-06-24 | 2005-02-03 | Amgen Inc. | 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases |
WO2005010008A1 (en) * | 2003-07-24 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
US6855719B1 (en) | 1999-08-21 | 2005-02-15 | Astrazeneca Ab | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives |
WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2005026158A1 (en) * | 2003-09-16 | 2005-03-24 | Novartis Ag | 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
EP1518855A1 (en) * | 2002-06-28 | 2005-03-30 | Yamanouchi Pharmaceutical Co. Ltd. | Diaminopyrimidinecarboxa mide derivative |
JP2005516046A (en) * | 2002-02-01 | 2005-06-02 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4-pyrimidinediamine compounds and their uses |
WO2005016893A3 (en) * | 2003-07-30 | 2005-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
US6924290B2 (en) | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
WO2005080350A1 (en) * | 2004-02-23 | 2005-09-01 | Glaxo Group Limited | Pyrimidine derivatives as cannabinoid receptor modulators |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2005099711A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US7034019B2 (en) | 2000-05-08 | 2006-04-25 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
EP1663242A2 (en) * | 2003-08-07 | 2006-06-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
WO2006061415A1 (en) * | 2004-12-08 | 2006-06-15 | Janssen Pharmaceutica N.V. | 2,4 (4,6) pyrimidine derivatives |
US7074789B2 (en) | 1999-10-07 | 2006-07-11 | Amgen Inc. | Kinase inhibitors |
EP1698627A1 (en) * | 2000-09-15 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
WO2006123113A2 (en) * | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
US7145008B2 (en) | 2004-05-14 | 2006-12-05 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
FR2888239A1 (en) * | 2005-07-11 | 2007-01-12 | Sanofi Aventis Sa | New 2,4-dianilinopyrimidine derivatives are kappa B kinase inhibitors, useful to treat or prevent e.g. inflammatory diseases, diabetes, cancer resistant to cytotoxic agents, solid or liquid tumors and in cancer chemotherapy |
WO2007006926A2 (en) * | 2005-07-11 | 2007-01-18 | Sanofi-Aventis | Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors |
US7166599B2 (en) | 2001-10-17 | 2007-01-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Trisubstituted pyrimidines |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
US7208499B2 (en) | 2004-05-14 | 2007-04-24 | Pfizer Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
US7235562B2 (en) | 2004-05-14 | 2007-06-26 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2007071455A1 (en) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine-substituted pyrimidines , their preparation and use as drugs |
WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7282504B2 (en) | 2000-02-17 | 2007-10-16 | Amgen Inc. | Kinase inhibitors |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
WO2008049123A2 (en) | 2006-10-19 | 2008-04-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
WO2008111441A1 (en) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
US7427626B2 (en) | 2003-05-16 | 2008-09-23 | Astrazeneca Ab | 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors |
US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
US7446105B2 (en) | 2002-03-09 | 2008-11-04 | Astrazeneca Ab | Pyrimidine compounds |
US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7465728B2 (en) | 2002-03-09 | 2008-12-16 | Astrazeneca Ab | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity |
US7485638B2 (en) | 2002-03-09 | 2009-02-03 | Astrazeneca Ab | Pyrimidine compounds |
US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US7563787B2 (en) | 2005-09-30 | 2009-07-21 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
US7579344B2 (en) | 2003-05-16 | 2009-08-25 | Astrazeneca Ab | Pyrimidine derivatives possessing cell-cycle inhibitors activity |
US7579349B2 (en) | 2003-10-17 | 2009-08-25 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
WO2009105675A1 (en) | 2008-02-22 | 2009-08-27 | Rigel Pharmaceuticals, Inc. | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
US7635701B2 (en) | 2002-08-21 | 2009-12-22 | Glaxo Group Limited | Pyrimidine derivatives and their use as CB2 modulators |
US7648986B2 (en) | 2002-01-10 | 2010-01-19 | Bayer Healthcare Llc | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
AU2006201228B2 (en) * | 2000-12-21 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazole Compounds Useful as Protein Kinase Inhibitors |
US7655652B2 (en) | 2004-02-03 | 2010-02-02 | Astrazeneca Ab | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation |
WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
US7705009B2 (en) | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
EP2179991A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179992A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179993A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
US7759357B2 (en) | 2002-02-01 | 2010-07-20 | Novartis Ag | Phenylpyrimidine amines as IgE inhibitors |
DE102009001438A1 (en) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome |
DE102009015070A1 (en) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7851480B2 (en) | 2004-11-24 | 2010-12-14 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US7910585B2 (en) | 2004-08-27 | 2011-03-22 | Novartis Ag | Pyrimidine derivatives |
EP2316459A1 (en) * | 2002-07-29 | 2011-05-04 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
WO2011065800A2 (en) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same |
US20110212077A1 (en) * | 2005-11-01 | 2011-09-01 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
DE102010014426A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
DE102010014427A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluoromethyl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances |
US8039479B2 (en) | 2006-12-08 | 2011-10-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8088784B2 (en) | 2005-10-28 | 2012-01-03 | Astrazeneca Ab | 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8129403B2 (en) | 2005-02-16 | 2012-03-06 | Astrazeneca Ab | Chemical compounds |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
WO2012061418A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
AU2006309013B2 (en) * | 2005-11-01 | 2012-06-28 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8268829B2 (en) | 2002-06-20 | 2012-09-18 | Vertex Pharmaceuticals Inc. | Substituted pyrimidines useful as protein kinase inhibitors |
US8273772B2 (en) | 2005-01-19 | 2012-09-25 | Bristol-Myers Squibb Company | Heteroaryl compounds as P2Y1 receptor inhibitors |
US8318736B2 (en) | 2006-12-29 | 2012-11-27 | Janssen R&D Ireland | HIV inhibiting 5,6-substituted pyrimidines |
US8404692B2 (en) | 2005-10-14 | 2013-03-26 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds |
US8486966B2 (en) | 2007-05-04 | 2013-07-16 | Astrazeneca Ab | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer |
US8507510B2 (en) | 2003-10-16 | 2013-08-13 | Bayer Intellectual Property Gmbh | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
KR101297924B1 (en) * | 2002-07-29 | 2013-08-20 | 리겔 파마슈티칼스, 인크. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
WO2013139734A1 (en) | 2012-03-21 | 2013-09-26 | Bayer Intellectual Property Gmbh | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours |
US8575342B2 (en) | 2004-09-30 | 2013-11-05 | Tibotech Pharmaceuticals Ltd. | HIV inhibiting 5-heterocyclyl pyrimidines |
US8598361B2 (en) | 2007-07-31 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof |
TWI421248B (en) * | 2004-08-20 | 2014-01-01 | Boehringer Ingelheim Int | Pyrimidines as plk inhibitors |
US8669081B2 (en) * | 2002-03-15 | 2014-03-11 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
WO2014085225A1 (en) * | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
WO2014144169A1 (en) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
US8933089B2 (en) | 2006-03-30 | 2015-01-13 | Janssen R & D Ireland | HIV inhibiting 5-amido substituted pyrimidines |
US8946248B2 (en) | 2004-09-30 | 2015-02-03 | Janssen R&D Ireland | HIV inhibiting 5-substituted pyrimidines |
US8952027B2 (en) | 2008-04-16 | 2015-02-10 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US9006243B2 (en) | 2006-12-29 | 2015-04-14 | Janssen R&D Ireland | HIV inhibiting 6-substituted pyrimidines |
US9012461B2 (en) | 2011-02-17 | 2015-04-21 | Cancer Therapeutics Crc Pty Ltd | FAK inhibitors |
AU2012230091B2 (en) * | 2005-11-01 | 2015-04-23 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
US9120761B2 (en) | 2011-02-17 | 2015-09-01 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
US9150546B2 (en) | 2009-02-13 | 2015-10-06 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical composition comprising the same |
EP2473486B1 (en) | 2009-09-02 | 2015-10-28 | Vifor (International) Ag | Pyrimidines as hepcidine antagonists |
US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US9376398B2 (en) | 2012-05-18 | 2016-06-28 | Sumitomo Dainippon Pharma Co., Ltd | Carboxylic acid compounds |
US9375402B2 (en) | 2010-06-29 | 2016-06-28 | Verastem, Inc. | Oral formulations of kinase inhibitors |
US9505719B2 (en) | 2010-06-30 | 2016-11-29 | Verastem, Inc. | Synthesis and use of kinase inhibitors |
US9550763B2 (en) | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
US9593082B2 (en) | 2005-06-08 | 2017-03-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
US9718790B2 (en) | 2010-08-10 | 2017-08-01 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same |
US9732060B2 (en) | 2013-06-14 | 2017-08-15 | Shionogi & Co., Ltd. | Aminotriazine derivative and pharmaceutical composition comprising the same |
US10391094B2 (en) | 2010-11-07 | 2019-08-27 | Impact Biomedicines, Inc. | Compositions and methods for treating myelofibrosis |
WO2019177375A1 (en) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient |
AU2020260512B2 (en) * | 2015-06-11 | 2022-07-21 | Xiangqun Xie | P62-zz chemical inhibitor |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
CN115677595A (en) * | 2022-10-26 | 2023-02-03 | 江苏睿实生物科技有限公司 | Preparation method of 2,4, 5-trichloropyrimidine |
WO2023214772A1 (en) * | 2022-05-03 | 2023-11-09 | 한국화학연구원 | Compound including 2,4-diaminopyridine, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69933680T2 (en) * | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | PYRIMIDINE COMPOUNDS |
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002102313A2 (en) * | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
ES2437391T3 (en) * | 2002-02-06 | 2014-01-10 | Vertex Pharmaceuticals, Inc. | Heteroaryl compounds useful as GSK-3 inhibitors |
WO2004072029A2 (en) * | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
CL2004000303A1 (en) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | COMPOUNDS DERIVED FROM PYRIMIDINS AND TRIAZINES; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND ITS USE TO INHIBIT HIV REPLICATION. |
US7592340B2 (en) * | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
EP1749827A4 (en) * | 2004-03-30 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | Anti-tumor agent |
CA2566531A1 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (en) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine derivatives as PLK inhibitors |
TW200626560A (en) * | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines |
GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
MX2007007272A (en) * | 2004-12-17 | 2007-07-11 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors. |
WO2007027238A2 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
AU2006274733B2 (en) * | 2005-07-30 | 2010-09-16 | Astrazeneca Ab | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
EP1917259B1 (en) * | 2005-08-18 | 2012-01-25 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
WO2007032445A1 (en) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | Protein kinase inhibitors |
CN103145702A (en) * | 2005-11-03 | 2013-06-12 | 顶点医药品公司 | Aminopyrimidines useful as kinase inhibitors |
BRPI0620324A2 (en) | 2005-12-21 | 2011-11-08 | Pfizer Prod Inc | pyrimidine derivatives, pharmaceutical composition and use thereof |
AR060890A1 (en) * | 2006-05-15 | 2008-07-23 | Boehringer Ingelheim Int | COMPOUNDS DERIVED FROM PIRIMIDINE AND PHARMACEUTICAL COMPOSITION BASED ON THEM |
MX2009004426A (en) | 2006-10-23 | 2009-08-12 | Cephalon Inc | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors. |
DE602007004750D1 (en) * | 2006-11-02 | 2010-03-25 | Vertex Pharma | AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINOPYRIDINES AND AMINOPYRIMIDINES |
MX2009006081A (en) * | 2006-12-08 | 2009-06-17 | Irmc Llc | Compounds and compositions as protein kinase inhibitors. |
ES2347721T3 (en) * | 2006-12-19 | 2010-11-03 | Vertex Pharmaceuticals, Inc. | USEFUL AMINOPIRIMIDINS AS PROTEIN QUINASE INHIBITORS. |
NZ579485A (en) * | 2007-03-09 | 2012-02-24 | Vertex Pharma | Aminopyrimidines useful as inhibitors of protein kinases |
EP2134707B1 (en) * | 2007-03-09 | 2013-09-11 | Vertex Pharmaceuticals, Inc. | Aminopyrimidines useful as inhibitors of protein kinases |
NZ579483A (en) | 2007-03-09 | 2012-07-27 | Vertex Pharma | Aminopyridines useful as inhibitors of protein kinases |
WO2008128009A2 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
MX2009011811A (en) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors. |
CA2685876A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
MX2009011812A (en) * | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopyrimidines useful as kinase inhibitors. |
AU2008257044A1 (en) * | 2007-05-24 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
RU2536584C2 (en) | 2008-06-27 | 2014-12-27 | Авила Терапьютикс, Инк. | Heteroaryl compounds and using them |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AU2009288200A1 (en) * | 2008-09-03 | 2010-03-11 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
JP5738292B2 (en) * | 2009-07-28 | 2015-06-24 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibition of the JAK pathway |
WO2011019943A1 (en) * | 2009-08-12 | 2011-02-17 | Poniard Pharmaceuticals, Inc. | Method of promoting apoptosis and inhibiting metastasis |
EP2580320B1 (en) | 2010-06-14 | 2018-08-01 | The Scripps Research Institute | Reprogramming of cells to a new fate |
SG187796A1 (en) | 2010-08-10 | 2013-03-28 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
JP5956999B2 (en) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Heteroaryl compounds and uses thereof |
TWI632134B (en) | 2010-11-01 | 2018-08-11 | 阿維拉製藥公司 | Heterocyclic compounds and uses thereof |
WO2012064706A1 (en) | 2010-11-10 | 2012-05-18 | Avila Therapeutics, Inc. | Mutant-selective egfr inhibitors and uses thereof |
TW201325593A (en) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | Methods of treating a BRUTON'S tyrosine kinase disease or disorder |
SG11201405691WA (en) | 2012-03-15 | 2014-10-30 | Celgene Avilomics Res Inc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
PT2825042T (en) | 2012-03-15 | 2018-11-16 | Celgene Car Llc | Salts of an epidermal growth factor receptor kinase inhibitor |
IN2014DN09610A (en) * | 2012-05-22 | 2015-07-31 | Univ North Carolina | |
KR102205914B1 (en) * | 2012-11-08 | 2021-01-20 | 브리스톨-마이어스 스큅 컴퍼니 | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
CN103059030B (en) * | 2012-12-28 | 2015-04-29 | 北京师范大学 | Pyrimidine compound with effect of adhesion kinase inhibition and preparation method and application thereof |
ES2805359T3 (en) | 2013-02-08 | 2021-02-11 | Celgene Car Llc | ERK inhibitors and their uses |
CN103333119A (en) * | 2013-05-28 | 2013-10-02 | 中国药科大学 | 1,2-dihydro-6-methyl-4-substituted amino-5-pyrimidinecarboxylic acid compound and its preparation method and use |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
MX2017003359A (en) | 2014-09-17 | 2017-11-22 | Celgene Car Llc | Mk2 inhibitors and uses thereof. |
CN106588885B (en) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2- replaces aromatic ring-pyridine derivatives and preparation and application |
CN107903256B (en) * | 2017-11-29 | 2019-11-15 | 南方医科大学 | A kind of 2,4- di-amino-pyrimidine and its application containing substituted thiazole |
KR20190108080A (en) * | 2018-03-13 | 2019-09-23 | 보로노이바이오 주식회사 | 2,4,5-substituted pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer or inflammatory disease in containing the same as an active ingredient |
CN112390760B (en) * | 2020-10-15 | 2022-07-29 | 北京师范大学 | FAK-targeting compound and preparation method and application thereof |
TW202333667A (en) * | 2021-12-13 | 2023-09-01 | 大陸商希格生科(深圳)有限公司 | Pyrimidine or pyridine derivative and pharmaceutical use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018887A1 (en) * | 1990-06-06 | 1991-12-12 | Smithkline Beecham Intercredit B.V. | Diaminopyrimidine compounds |
WO1999050250A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946956A (en) | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
ATE159009T1 (en) | 1991-05-10 | 1997-10-15 | Rhone Poulenc Rorer Int | BIS MONO- AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH AN INHIBITING EFFECT ON THE EGF AND/OR PDGF RECEPTOR TYROSINKINASE |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
ES2149213T3 (en) | 1992-10-05 | 2000-11-01 | Ube Industries | PIRIMIDINE COMPOUND. |
US5728708A (en) | 1993-10-01 | 1998-03-17 | Novartis Corporation | Pharmacologically active pyridine derivatives and processes for the preparation thereof |
EP0672035A1 (en) | 1993-10-01 | 1995-09-20 | Novartis AG | Pyrimidineamine derivatives and processes for the preparation thereof |
JP3588116B2 (en) | 1993-10-01 | 2004-11-10 | ノバルティス アクチェンゲゼルシャフト | Pharmacologically active pyrimidineamine derivatives and process for their production |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
DE69530989T2 (en) | 1994-08-13 | 2004-05-19 | Yuhan Corp. | NEW PYRIMID DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
AU707323B2 (en) | 1995-03-10 | 1999-07-08 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6096739A (en) | 1996-03-25 | 2000-08-01 | Smithkline Beecham Corporation | Treatment for CNS injuries |
WO1997040017A2 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
DE69733135T2 (en) | 1996-06-10 | 2006-03-02 | Merck & Co., Inc. | SUBSTITUTED IMIDAZOLE WITH CYTOKININ INHIBIRENT EFFECT |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
WO1998016230A1 (en) | 1996-10-17 | 1998-04-23 | Smithkline Beecham Corporation | Methods for reversibly inhibiting myelopoiesis in mammalian tissue |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
DE19710435A1 (en) | 1997-03-13 | 1998-09-17 | Hoechst Ag | Use of pyrimidine derivatives for the prevention of cancer alone or in combination with other therapeutic measures |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
AU742293B2 (en) | 1997-06-12 | 2001-12-20 | Aventis Pharma Limited | Imidazolyl-cyclic acetals |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
EP1019391A1 (en) | 1997-10-02 | 2000-07-19 | Merck & Co. Inc. | Inhibitors of prenyl-protein transferase |
JP2001519381A (en) | 1997-10-10 | 2001-10-23 | インペリアル・カレッジ・イノベイションズ・リミテッド | Use of CSAID ™ compounds for management of uterine contractions |
AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
AU1924699A (en) | 1997-12-19 | 1999-07-12 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses |
GB2334461B (en) | 1998-02-20 | 2002-01-23 | Bespak Plc | Inhalation apparatus |
EP1107958B1 (en) | 1998-08-29 | 2006-08-16 | AstraZeneca AB | Pyrimidine compounds |
DE69933680T2 (en) * | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | PYRIMIDINE COMPOUNDS |
CN1335849A (en) | 1998-09-18 | 2002-02-13 | 巴斯福股份公司 | Pyrrolopyrimidines as protein kinase inhibitors |
CZ2001959A3 (en) | 1998-09-18 | 2001-12-12 | Basf Aktiengesellschaft | 4-Aminopyrrolopyrimidines functioning as kinase inhibitors |
US6531477B1 (en) | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
WO2000026209A1 (en) | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
ES2246829T3 (en) | 1999-02-01 | 2006-03-01 | Cv Therapeutics Inc | PURINIC INHIBITORS OF CINASA 2 AND OF IKB-ALFA CYCLINE DEPENDENTS. |
GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
US6627633B2 (en) | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
DE60024480T2 (en) | 1999-10-27 | 2006-07-27 | Novartis Ag | THIAZOL AND IMIDAZO [4,5-B] PYRIDINE COMPOUNDS AND THEIR USE AS PHARMACEUTICALS |
KR20020050294A (en) | 1999-11-22 | 2002-06-26 | 피터 기딩스 | Novel compounds |
DE60043397D1 (en) | 1999-12-28 | 2010-01-07 | Pharmacopeia Inc | CYTOKINE, PARTICULAR TNF-ALPHA, HEMMER |
CN1429222A (en) | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | Kinase inhibitors |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
-
1998
- 1998-12-24 GB GBGB9828511.7A patent/GB9828511D0/en not_active Ceased
-
1999
- 1999-12-20 ES ES99962375T patent/ES2228145T3/en not_active Expired - Lifetime
- 1999-12-20 KR KR1020017007971A patent/KR100663773B1/en not_active IP Right Cessation
- 1999-12-20 IL IL14380699A patent/IL143806A0/en unknown
- 1999-12-20 JP JP2000591012A patent/JP2002533446A/en active Pending
- 1999-12-20 AT AT99962375T patent/ATE277020T1/en not_active IP Right Cessation
- 1999-12-20 WO PCT/GB1999/004325 patent/WO2000039101A1/en active IP Right Grant
- 1999-12-20 DK DK99962375T patent/DK1140860T3/en active
- 1999-12-20 BR BR9916590-2A patent/BR9916590A/en not_active Application Discontinuation
- 1999-12-20 EP EP99962375A patent/EP1140860B1/en not_active Expired - Lifetime
- 1999-12-20 NZ NZ512118A patent/NZ512118A/en unknown
- 1999-12-20 AU AU18743/00A patent/AU763091B2/en not_active Ceased
- 1999-12-20 DE DE69920509T patent/DE69920509T2/en not_active Expired - Fee Related
- 1999-12-20 CA CA002352896A patent/CA2352896A1/en not_active Abandoned
- 1999-12-20 PT PT99962375T patent/PT1140860E/en unknown
- 1999-12-20 US US09/868,602 patent/US6593326B1/en not_active Expired - Fee Related
- 1999-12-20 CN CNB998162787A patent/CN1285580C/en not_active Expired - Fee Related
-
2001
- 2001-05-29 ZA ZA200104413A patent/ZA200104413B/en unknown
- 2001-06-17 IL IL143806A patent/IL143806A/en not_active IP Right Cessation
- 2001-06-19 NO NO20013038A patent/NO319815B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018887A1 (en) * | 1990-06-06 | 1991-12-12 | Smithkline Beecham Intercredit B.V. | Diaminopyrimidine compounds |
WO1999050250A1 (en) * | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 95, no. 11, 1981, Columbus, Ohio, US; abstract no. 97712f, GHOSH,D.: "2,4-BIS(ARYLAMINO)-6-METHYLPYRIMIDINES AS ANTIMICROBIAL AGENTS" page 648; XP002109184 * |
J.INDIAN CHEM. SOC., vol. 58, no. 5, 1981, INDIA, pages 512 - 13 * |
Cited By (429)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US6670368B1 (en) | 1999-04-06 | 2003-12-30 | Astrazeneca Ab | Pyrimidine compounds with pharmaceutical activity |
US9382219B2 (en) | 1999-04-15 | 2016-07-05 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US8993567B2 (en) | 1999-04-15 | 2015-03-31 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7091223B2 (en) | 1999-04-15 | 2006-08-15 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6596746B1 (en) | 1999-04-15 | 2003-07-22 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6979694B2 (en) | 1999-04-15 | 2005-12-27 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7153856B2 (en) | 1999-04-15 | 2006-12-26 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7189854B2 (en) | 1999-04-15 | 2007-03-13 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6855719B1 (en) | 1999-08-21 | 2005-02-15 | Astrazeneca Ab | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives |
US7074789B2 (en) | 1999-10-07 | 2006-07-11 | Amgen Inc. | Kinase inhibitors |
US7282504B2 (en) | 2000-02-17 | 2007-10-16 | Amgen Inc. | Kinase inhibitors |
US7067522B2 (en) | 2000-03-01 | 2006-06-27 | Astrazeneca Ab | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
WO2001064654A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | Pyrimidine compounds |
US6710052B2 (en) | 2000-03-01 | 2004-03-23 | Astrazeneca | Pyrimidine compounds |
US6649608B2 (en) | 2000-03-01 | 2003-11-18 | Astrazeneca Ab | 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents |
WO2001064655A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
US7153964B2 (en) | 2000-03-01 | 2006-12-26 | Astrazeneca Ab | Pyrimidine compounds |
US6838464B2 (en) | 2000-03-01 | 2005-01-04 | Astrazeneca Ab | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
WO2001064656A1 (en) | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
KR100771455B1 (en) * | 2000-03-01 | 2007-10-31 | 아스트라제네카 아베 | 2,4 -dihetero-arylamino-oxy-5-substituted pyrimidines as antineoplastic agents |
AU2001239414B2 (en) * | 2000-03-28 | 2004-09-02 | Astrazeneca Ab | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
KR100802367B1 (en) | 2000-03-28 | 2008-02-13 | 아스트라제네카 아베 | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
WO2001072717A1 (en) * | 2000-03-28 | 2001-10-04 | Astrazeneca Ab | 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
US6906065B2 (en) | 2000-03-28 | 2005-06-14 | Astrazeneca Ab | 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
US7763631B2 (en) | 2000-05-08 | 2010-07-27 | Janssen Pharmaceutica Nv | Prodrugs of HIV replication inhibiting pyrimidines |
US7276510B2 (en) | 2000-05-08 | 2007-10-02 | Janssen Pharmaceutica, Inc. | HIV replication inhibitors |
WO2001085700A3 (en) * | 2000-05-08 | 2002-02-07 | Janssen Pharmaceutica Nv | Hiv replication inhibiting pyrimidines and triazines |
US7034019B2 (en) | 2000-05-08 | 2006-04-25 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
KR100783447B1 (en) * | 2000-07-11 | 2007-12-07 | 아스트라제네카 아베 | Pyrimidine derivatives |
WO2002004429A1 (en) * | 2000-07-11 | 2002-01-17 | Astrazeneca Ab | Pyrimidine derivatives |
US6908920B2 (en) | 2000-07-11 | 2005-06-21 | Astrazeneca Ab | Pyrimidine derivatives |
JP2004502763A (en) * | 2000-07-11 | 2004-01-29 | アストラゼネカ アクチボラグ | Pyrimidine derivatives |
US6822384B2 (en) | 2000-08-17 | 2004-11-23 | Lumera Corporation | Design and synthesis of advanced NLO materials for electro-optic applicators |
US7098330B2 (en) | 2000-09-15 | 2006-08-29 | Vertex Pharmaceuticals Incorporated | Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors |
WO2002022601A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022603A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022608A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
KR100896664B1 (en) * | 2000-09-15 | 2009-05-14 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrazole compounds useful as protein kinase inhibitors |
EP1698627A1 (en) * | 2000-09-15 | 2006-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022605A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7008948B2 (en) | 2000-09-15 | 2006-03-07 | Vertex Pharmaceuticals, Incorporated | Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors |
CN100355750C (en) * | 2000-09-15 | 2007-12-19 | 沃泰克斯药物股份有限公司 | Pyrazole compounds useful as protein kinase inhibitors |
US6696452B2 (en) | 2000-09-15 | 2004-02-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022604A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022606A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002022607A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002045652A2 (en) * | 2000-12-04 | 2002-06-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2002045652A3 (en) * | 2000-12-04 | 2002-08-22 | Merck & Co Inc | Tyrosine kinase inhibitors |
US7115597B2 (en) | 2000-12-04 | 2006-10-03 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7442699B2 (en) | 2000-12-06 | 2008-10-28 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
AU2001297619B2 (en) * | 2000-12-21 | 2006-06-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CN100408573C (en) * | 2000-12-21 | 2008-08-06 | 沃泰克斯药物股份有限公司 | Pyrazole compounds useful as protein kinase inhibitors |
KR100947185B1 (en) * | 2000-12-21 | 2010-03-15 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrazole compounds useful as protein kinase inhibitors and compositions comprising said compounds |
WO2002050065A2 (en) * | 2000-12-21 | 2002-06-27 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2006201267B2 (en) * | 2000-12-21 | 2010-07-29 | Vertex Pharmaceuticals Incorporated | Pyrazole Compounds Useful as Protein Kinase Inhibitors |
KR100909665B1 (en) * | 2000-12-21 | 2009-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same |
JP2009155352A (en) * | 2000-12-21 | 2009-07-16 | Vertex Pharmaceut Inc | Pyrazole compound useful as protein kinase inhibitor |
EP2264028A1 (en) * | 2000-12-21 | 2010-12-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002050066A2 (en) * | 2000-12-21 | 2002-06-27 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7858626B2 (en) | 2000-12-21 | 2010-12-28 | Glaxosmithkline Llc | Pyrimidineamines as angiogenesis modulators |
WO2002057259A2 (en) * | 2000-12-21 | 2002-07-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
KR100889246B1 (en) * | 2000-12-21 | 2009-03-19 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrazole compounds useful as protein kinase inhibitors and compositions comprising said compounds |
US6706717B2 (en) | 2000-12-21 | 2004-03-16 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
EP2311825A1 (en) * | 2000-12-21 | 2011-04-20 | GlaxoSmithKline LLC | Pyrimidineamines as angiogenesis modulators |
CN100436452C (en) * | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | Pyrazole compounds useful as protein kinase inhibitors |
WO2002059111A2 (en) * | 2000-12-21 | 2002-08-01 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7982037B2 (en) * | 2000-12-21 | 2011-07-19 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP2008189687A (en) * | 2000-12-21 | 2008-08-21 | Vertex Pharmaceut Inc | Pyrazole compound useful as protein kinase inhibitor |
US6727251B2 (en) | 2000-12-21 | 2004-04-27 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CN100406454C (en) * | 2000-12-21 | 2008-07-30 | 沃泰克斯药物股份有限公司 | Pyrazole compounds useful as protein kinase inhibitors. |
US6664247B2 (en) | 2000-12-21 | 2003-12-16 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
KR100847169B1 (en) * | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | Pyrimidineamines as angiogenesis modulators |
CN102250071A (en) * | 2000-12-21 | 2011-11-23 | 沃泰克斯药物股份有限公司 | Pyrazole compounds useful as protein kinase inhibitors |
KR100843114B1 (en) * | 2000-12-21 | 2008-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions comprising the same |
US8114885B2 (en) | 2000-12-21 | 2012-02-14 | Glaxosmithkline Llc | Chemical compounds |
WO2002059112A2 (en) * | 2000-12-21 | 2002-08-01 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6656939B2 (en) | 2000-12-21 | 2003-12-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6653300B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002059110A1 (en) * | 2000-12-21 | 2002-08-01 | Glaxo Group Limited | Pyrimidineamines as angiogenesis modulators |
WO2002062789A1 (en) * | 2000-12-21 | 2002-08-15 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002066461A1 (en) * | 2000-12-21 | 2002-08-29 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002068415A1 (en) * | 2000-12-21 | 2002-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CN100340555C (en) * | 2000-12-21 | 2007-10-03 | 沃泰克斯药物股份有限公司 | Pyrazole compounds useful as protein kinase inhibitors |
US6953795B2 (en) | 2000-12-21 | 2005-10-11 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
US6956045B2 (en) | 2000-12-21 | 2005-10-18 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
US6958336B2 (en) | 2000-12-21 | 2005-10-25 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
WO2002050065A3 (en) * | 2000-12-21 | 2002-10-24 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
US6653301B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7262203B2 (en) | 2000-12-21 | 2007-08-28 | Smithkline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
US7241781B2 (en) | 2000-12-21 | 2007-07-10 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
US7037926B2 (en) | 2000-12-21 | 2006-05-02 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of Tec family tyrosine kinases |
US8304414B2 (en) | 2000-12-21 | 2012-11-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2002246754B2 (en) * | 2000-12-21 | 2006-06-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2006201228B2 (en) * | 2000-12-21 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazole Compounds Useful as Protein Kinase Inhibitors |
AU2002255452B2 (en) * | 2000-12-21 | 2006-06-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
CN1307173C (en) * | 2000-12-21 | 2007-03-28 | 葛兰素集团有限公司 | Pyrimidineamines as angiogenesis modulators |
CZ304059B6 (en) * | 2000-12-21 | 2013-09-11 | Glaxo Group Limited | Pyrimidine derivative and pharmaceutical composition |
JP2013213068A (en) * | 2000-12-21 | 2013-10-17 | Vertex Pharmaceuticals Inc | Pyrazole compound useful as protein kinase inhibitor |
US8697698B2 (en) | 2000-12-21 | 2014-04-15 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002059111A3 (en) * | 2000-12-21 | 2003-01-09 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
WO2002050066A3 (en) * | 2000-12-21 | 2003-01-23 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
WO2002059112A3 (en) * | 2000-12-21 | 2003-02-06 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
WO2002057259A3 (en) * | 2000-12-21 | 2003-04-24 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
US7105530B2 (en) | 2000-12-21 | 2006-09-12 | Smithkline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
EP1702920A1 (en) * | 2000-12-21 | 2006-09-20 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7105670B2 (en) | 2001-01-22 | 2006-09-12 | Hoffmann-La Roche Inc. | Intermediates useful in the preparation of diaminothiazoles |
US7094896B2 (en) | 2001-01-22 | 2006-08-22 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
US6844341B2 (en) | 2001-02-17 | 2005-01-18 | Astrazeneca Ab | Pyrimidine derivatives for inhibition of cell proliferation |
WO2002079193A1 (en) * | 2001-03-29 | 2002-10-10 | Cyclacel Limited | Inhibitors of cyclin dependent kinases as anti-cancer agent |
US7262202B2 (en) | 2001-03-29 | 2007-08-28 | Cyclacel Limited | Inhibitors of cyclin dependent kinases as anti-cancer agent |
DE10127581A1 (en) * | 2001-05-29 | 2003-01-02 | Schering Ag | New 2-anilino-pyrimidine derivatives, are potent cyclin dependent kinase inhibitors, useful e.g. for treating cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections |
WO2002096888A1 (en) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
WO2002096887A1 (en) * | 2001-05-30 | 2002-12-05 | Astrazeneca Ab | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
US6939872B2 (en) | 2001-05-30 | 2005-09-06 | Astrazeneca Ab | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
US8044040B2 (en) | 2001-06-26 | 2011-10-25 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-alpha expression |
JP2004535447A (en) * | 2001-06-26 | 2004-11-25 | ブリストル−マイヤーズ スクイブ カンパニー | N-heterocyclic inhibitors of TNF-α expression |
WO2003018022A1 (en) * | 2001-08-22 | 2003-03-06 | Amgen Inc. | 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
WO2003026666A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
EP2090571A1 (en) | 2001-10-17 | 2009-08-19 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation |
WO2003032997A1 (en) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
US8420630B2 (en) | 2001-10-17 | 2013-04-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives |
US7709480B2 (en) | 2001-10-17 | 2010-05-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives |
US7166599B2 (en) | 2001-10-17 | 2007-01-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Trisubstituted pyrimidines |
US7173028B2 (en) | 2001-10-17 | 2007-02-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives |
EP2332924A1 (en) | 2001-10-17 | 2011-06-15 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation |
WO2003048133A1 (en) * | 2001-12-07 | 2003-06-12 | Astrazeneca Ab | Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) |
US7521453B2 (en) | 2001-12-07 | 2009-04-21 | Astrazeneca Ab | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-I) |
KR100930558B1 (en) * | 2001-12-07 | 2009-12-09 | 아스트라제네카 아베 | Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) |
US7648986B2 (en) | 2002-01-10 | 2010-01-19 | Bayer Healthcare Llc | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors |
US6924290B2 (en) | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
WO2003062227A1 (en) * | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US6943172B2 (en) | 2002-01-23 | 2005-09-13 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US9586908B2 (en) | 2002-02-01 | 2017-03-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10828301B2 (en) | 2002-02-01 | 2020-11-10 | Rigel Pharmceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8835430B2 (en) * | 2002-02-01 | 2014-09-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7655797B2 (en) | 2002-02-01 | 2010-02-02 | Rigel Pharmaceuticals, Inc. | Intermediates for making 2,4-pyrimidinediamine compounds |
US9040550B2 (en) | 2002-02-01 | 2015-05-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9018204B1 (en) | 2002-02-01 | 2015-04-28 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8334296B2 (en) | 2002-02-01 | 2012-12-18 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8822685B2 (en) | 2002-02-01 | 2014-09-02 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8410266B2 (en) * | 2002-02-01 | 2013-04-02 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
HRP20040684B1 (en) * | 2002-02-01 | 2014-07-04 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9133133B2 (en) | 2002-02-01 | 2015-09-15 | Rigel Pharmaceuticals, Inc. | 2,4-pyridinediamine compounds and their uses |
US7589200B2 (en) * | 2002-02-01 | 2009-09-15 | Rigel Pharmaceuticals, Inc. | 5-Fluoro-4N-phenyl-4-pyrimidineamine compounds |
US8148525B2 (en) * | 2002-02-01 | 2012-04-03 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7329672B2 (en) | 2002-02-01 | 2008-02-12 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7329671B2 (en) | 2002-02-01 | 2008-02-12 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7759357B2 (en) | 2002-02-01 | 2010-07-20 | Novartis Ag | Phenylpyrimidine amines as IgE inhibitors |
US7332484B2 (en) | 2002-02-01 | 2008-02-19 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9162989B2 (en) | 2002-02-01 | 2015-10-20 | Rigel Pharmaceuticals, Inc. | 2,4-Pyrimidinediamine compounds and their uses |
US8748597B2 (en) | 2002-02-01 | 2014-06-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US20120045454A1 (en) * | 2002-02-01 | 2012-02-23 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
JP2005516046A (en) * | 2002-02-01 | 2005-06-02 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4-pyrimidinediamine compounds and their uses |
US10709703B2 (en) | 2002-02-01 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8853397B2 (en) | 2002-02-01 | 2014-10-07 | Rigel Pharmacuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9346765B2 (en) | 2002-02-01 | 2016-05-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10682350B2 (en) | 2002-02-01 | 2020-06-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7803939B2 (en) | 2002-02-01 | 2010-09-28 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9416112B2 (en) | 2002-02-01 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9499493B2 (en) | 2002-02-01 | 2016-11-22 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7820819B2 (en) | 2002-02-01 | 2010-10-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7557210B2 (en) * | 2002-02-01 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10369148B2 (en) | 2002-02-01 | 2019-08-06 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
KR101037856B1 (en) * | 2002-02-01 | 2011-06-01 | 리겔 파마슈티칼스, 인크. | 2,4-pyrimidinediamine compounds and their uses |
US10314840B2 (en) | 2002-02-01 | 2019-06-11 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US11007193B2 (en) | 2002-02-01 | 2021-05-18 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9913842B2 (en) | 2002-02-01 | 2018-03-13 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
JP4658477B2 (en) * | 2002-02-01 | 2011-03-23 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4-pyrimidinediamine compounds and their uses |
US9540334B2 (en) | 2002-02-01 | 2017-01-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7459455B2 (en) | 2002-02-08 | 2008-12-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
WO2003066601A1 (en) * | 2002-02-08 | 2003-08-14 | Smithkline Beecham Corporation | Pyrimidine compounds |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
US7446105B2 (en) | 2002-03-09 | 2008-11-04 | Astrazeneca Ab | Pyrimidine compounds |
US7442697B2 (en) | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
US7485638B2 (en) | 2002-03-09 | 2009-02-03 | Astrazeneca Ab | Pyrimidine compounds |
US7465728B2 (en) | 2002-03-09 | 2008-12-16 | Astrazeneca Ab | Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with CDK inhibitory activity |
WO2003076437A1 (en) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
DE10212100A1 (en) * | 2002-03-11 | 2003-10-23 | Schering Ag | New 2-aminopyrimidine derivatives are cyclin-dependent kinase inhibitors useful for treating e.g. cancer, autoimmune diseases, cardiovascular diseases, infectious diseases or viral infections |
US8669081B2 (en) * | 2002-03-15 | 2014-03-11 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
EP2308855A1 (en) * | 2002-03-15 | 2011-04-13 | Novartis AG | 2,4-Diaminopyrimidine derivatives |
US8431589B2 (en) | 2002-03-15 | 2013-04-30 | Novartis Ag | 2,4-diaminopyrimidine derivatives |
WO2003078404A1 (en) * | 2002-03-15 | 2003-09-25 | Novartis Ag | Pyrimidine derivatives |
US7943627B2 (en) | 2002-03-15 | 2011-05-17 | Novartis Ag | 2,4-diaminopyrimidine derivatives |
US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
WO2004046118A3 (en) * | 2002-05-06 | 2004-08-12 | Bayer Pharmaceuticals Corp | 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders |
WO2004046118A2 (en) * | 2002-05-06 | 2004-06-03 | Bayer Pharmaceuticals Corporation | 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders |
WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
WO2003106451A1 (en) * | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
US8268829B2 (en) | 2002-06-20 | 2012-09-18 | Vertex Pharmaceuticals Inc. | Substituted pyrimidines useful as protein kinase inhibitors |
EP1518855A1 (en) * | 2002-06-28 | 2005-03-30 | Yamanouchi Pharmaceutical Co. Ltd. | Diaminopyrimidinecarboxa mide derivative |
US8012959B2 (en) | 2002-06-28 | 2011-09-06 | Astellas Pharma Inc. | Diaminopyrimidinecarboxamide derivative |
EP1518855A4 (en) * | 2002-06-28 | 2007-03-14 | Astellas Pharma Inc | Diaminopyrimidinecarboxa mide derivative |
US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
US8557806B2 (en) | 2002-07-29 | 2013-10-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7825116B2 (en) | 2002-07-29 | 2010-11-02 | Rigel Pharmaceuticals, Inc. | N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines |
AU2003265336B2 (en) * | 2002-07-29 | 2008-06-19 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
RU2659777C2 (en) * | 2002-07-29 | 2018-07-04 | Райджел Фармасьютикалз, Инк. | Methods for treatment or prevention of autoimmune diseases with use of 2,4-pyrimidinediamine |
KR101297924B1 (en) * | 2002-07-29 | 2013-08-20 | 리겔 파마슈티칼스, 인크. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7812029B1 (en) | 2002-07-29 | 2010-10-12 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
RU2659777C9 (en) * | 2002-07-29 | 2019-09-03 | Райджел Фармасьютикалз, Инк. | Methods for treatment or prevention of autoimmune diseases with use of 2,4-pyrimidinediamine |
WO2004014382A1 (en) * | 2002-07-29 | 2004-02-19 | Rigel Pharmaceuticals | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
EP2316459A1 (en) * | 2002-07-29 | 2011-05-04 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
HRP20050089B1 (en) * | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7517886B2 (en) | 2002-07-29 | 2009-04-14 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
AU2003265336B8 (en) * | 2002-07-29 | 2009-04-23 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7635701B2 (en) | 2002-08-21 | 2009-12-22 | Glaxo Group Limited | Pyrimidine derivatives and their use as CB2 modulators |
US7312225B2 (en) | 2002-08-21 | 2007-12-25 | Bayer Schering Pharma Ag | Macrocyclic pyrimidines, their production and use as pharmaceutical agents |
CN100357295C (en) * | 2002-08-21 | 2007-12-26 | 舍林股份公司 | Macrocyclic pyrimidines, their production and use as pharmaceutical agents |
WO2004026881A1 (en) * | 2002-08-21 | 2004-04-01 | Schering Aktiengesellschaft | Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments |
WO2004056786A3 (en) * | 2002-12-20 | 2004-10-21 | Pfizer Prod Inc | Pyrimidine derivates for the treatment of abnormal cell growth |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7351712B2 (en) | 2002-12-20 | 2008-04-01 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
NL1025071C2 (en) * | 2002-12-20 | 2004-12-30 | Pfizer Prod Inc | Compounds for the treatment of abnormal cell growth. |
WO2004056786A2 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivates for the treatment of abnormal cell growth |
EA013248B1 (en) * | 2002-12-20 | 2010-04-30 | Пфайзер Продактс Инк. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7674796B2 (en) | 2002-12-20 | 2010-03-09 | Pfizer Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7109335B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2004056807A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
AP2385A (en) * | 2002-12-20 | 2012-03-23 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
US7741336B2 (en) | 2002-12-20 | 2010-06-22 | Pfizer Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
US7615634B2 (en) | 2003-02-10 | 2009-11-10 | Hoffmann-La Roche Inc. | 4-aminopyrimidine-5-one derivatives |
US7514446B2 (en) | 2003-02-20 | 2009-04-07 | Smithkline Beecham Corporation | Pyrimidine compounds |
WO2004074244A2 (en) * | 2003-02-20 | 2004-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
WO2004074244A3 (en) * | 2003-02-20 | 2004-11-11 | Smithkline Beecham Corp | Pyrimidine compounds |
JP2006518386A (en) * | 2003-02-20 | 2006-08-10 | スミスクライン ビーチャム コーポレーション | Pyrimidine compounds |
WO2004080980A1 (en) * | 2003-03-14 | 2004-09-23 | Novartis Ag | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
EP2275413A1 (en) * | 2003-03-14 | 2011-01-19 | Novartis AG | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. |
US7964592B2 (en) | 2003-03-14 | 2011-06-21 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
CN1788001B (en) * | 2003-03-14 | 2010-09-22 | 诺瓦提斯公司 | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
US8263590B2 (en) | 2003-03-14 | 2012-09-11 | Carlos Garcia-Echeverria | Pyrimidine derivatives |
US7427626B2 (en) | 2003-05-16 | 2008-09-23 | Astrazeneca Ab | 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors |
US7579344B2 (en) | 2003-05-16 | 2009-08-25 | Astrazeneca Ab | Pyrimidine derivatives possessing cell-cycle inhibitors activity |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
WO2005009443A1 (en) * | 2003-06-24 | 2005-02-03 | Amgen Inc. | 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2005010008A1 (en) * | 2003-07-24 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
US7238701B2 (en) | 2003-07-24 | 2007-07-03 | Bayer Pharmaceuticals Corporation | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
US9751893B2 (en) | 2003-07-30 | 2017-09-05 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
JP2007500722A (en) * | 2003-07-30 | 2007-01-18 | リゲル ファーマシューティカルズ,インコーポレイティド | Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
WO2005016893A3 (en) * | 2003-07-30 | 2005-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
JP4886511B2 (en) * | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
KR101201603B1 (en) | 2003-07-30 | 2012-11-14 | 리겔 파마슈티칼스, 인크. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
US8809341B2 (en) | 2003-08-07 | 2014-08-19 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
US9598432B2 (en) | 2003-08-07 | 2017-03-21 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
US7884111B2 (en) | 2003-08-07 | 2011-02-08 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
EP1663242A2 (en) * | 2003-08-07 | 2006-06-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
US7893074B2 (en) | 2003-08-15 | 2011-02-22 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
EP2287156A1 (en) * | 2003-08-15 | 2011-02-23 | Novartis AG | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
EP2266977A1 (en) * | 2003-09-16 | 2010-12-29 | Novartis AG | 2,4-di[(hetero)arylamino]-pyrimidine derivatives as zap-70 and/or syk inhibitors |
US7671063B2 (en) | 2003-09-16 | 2010-03-02 | Novartis Ag | 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors |
US8283356B2 (en) | 2003-09-16 | 2012-10-09 | Novartis Ag | 2,4- Di(hetero)-arylamino-pyrimidine derivatives as ZAP-70 and/or SYK inhibitors |
WO2005026158A1 (en) * | 2003-09-16 | 2005-03-24 | Novartis Ag | 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors |
AU2004272283B9 (en) * | 2003-09-16 | 2008-10-23 | Novartis Ag | 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors |
AU2004272283B2 (en) * | 2003-09-16 | 2008-10-02 | Novartis Ag | 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors |
US8507510B2 (en) | 2003-10-16 | 2013-08-13 | Bayer Intellectual Property Gmbh | Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
US7579349B2 (en) | 2003-10-17 | 2009-08-25 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
US7655652B2 (en) | 2004-02-03 | 2010-02-02 | Astrazeneca Ab | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation |
WO2005080350A1 (en) * | 2004-02-23 | 2005-09-01 | Glaxo Group Limited | Pyrimidine derivatives as cannabinoid receptor modulators |
WO2005099711A1 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US7560464B2 (en) | 2004-04-13 | 2009-07-14 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
US7235562B2 (en) | 2004-05-14 | 2007-06-26 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7208499B2 (en) | 2004-05-14 | 2007-04-24 | Pfizer Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7145008B2 (en) | 2004-05-14 | 2006-12-05 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
EP1781640B1 (en) * | 2004-08-20 | 2015-01-07 | Boehringer Ingelheim International GmbH | 2,4-di(aminophenyl)pyrimidine derivatives as plk inhibitors |
TWI421248B (en) * | 2004-08-20 | 2014-01-01 | Boehringer Ingelheim Int | Pyrimidines as plk inhibitors |
US7910585B2 (en) | 2004-08-27 | 2011-03-22 | Novartis Ag | Pyrimidine derivatives |
US8575342B2 (en) | 2004-09-30 | 2013-11-05 | Tibotech Pharmaceuticals Ltd. | HIV inhibiting 5-heterocyclyl pyrimidines |
US8946248B2 (en) | 2004-09-30 | 2015-02-03 | Janssen R&D Ireland | HIV inhibiting 5-substituted pyrimidines |
US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
US7851480B2 (en) | 2004-11-24 | 2010-12-14 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
NO340130B1 (en) * | 2004-12-08 | 2017-03-13 | Janssen Pharmaceutica Nv | 2,4 (4,6) pyrimidine derivatives |
JP2008523033A (en) * | 2004-12-08 | 2008-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2,4 (4,6) pyrimidine derivatives |
EA013368B1 (en) * | 2004-12-08 | 2010-04-30 | Янссен Фармацевтика Н.В. | 2,4 (4,6) pyrimidine derivatives |
US8148388B2 (en) | 2004-12-08 | 2012-04-03 | Janssen Pharmaceutica, N.V. | 2,4 (4,6) pyrimidine derivatives |
WO2006061415A1 (en) * | 2004-12-08 | 2006-06-15 | Janssen Pharmaceutica N.V. | 2,4 (4,6) pyrimidine derivatives |
US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7989448B2 (en) | 2005-01-19 | 2011-08-02 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US10577381B2 (en) | 2005-01-19 | 2020-03-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8273772B2 (en) | 2005-01-19 | 2012-09-25 | Bristol-Myers Squibb Company | Heteroaryl compounds as P2Y1 receptor inhibitors |
US20200270271A1 (en) * | 2005-01-19 | 2020-08-27 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8785437B2 (en) | 2005-01-19 | 2014-07-22 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US9532998B2 (en) | 2005-01-19 | 2017-01-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7563892B1 (en) | 2005-01-19 | 2009-07-21 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4 pyrimidinediamine compounds and their uses |
US8211889B2 (en) | 2005-01-19 | 2012-07-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7538108B2 (en) | 2005-01-19 | 2009-05-26 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8211888B2 (en) | 2005-01-19 | 2012-07-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US9266912B2 (en) | 2005-01-19 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8476263B2 (en) | 2005-01-19 | 2013-07-02 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8129403B2 (en) | 2005-02-16 | 2012-03-06 | Astrazeneca Ab | Chemical compounds |
US8481521B2 (en) | 2005-04-18 | 2013-07-09 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
WO2006123113A3 (en) * | 2005-05-16 | 2007-01-04 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
AU2006248780B2 (en) * | 2005-05-16 | 2010-06-03 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
US8114989B2 (en) | 2005-05-16 | 2012-02-14 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
WO2006123113A2 (en) * | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
US8399472B2 (en) | 2005-06-08 | 2013-03-19 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US10421752B2 (en) | 2005-06-08 | 2019-09-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US11827628B2 (en) | 2005-06-08 | 2023-11-28 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US11198689B2 (en) | 2005-06-08 | 2021-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9732073B2 (en) | 2005-06-08 | 2017-08-15 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9593082B2 (en) | 2005-06-08 | 2017-03-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9248190B2 (en) | 2005-06-08 | 2016-02-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8415365B2 (en) | 2005-06-08 | 2013-04-09 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
FR2888239A1 (en) * | 2005-07-11 | 2007-01-12 | Sanofi Aventis Sa | New 2,4-dianilinopyrimidine derivatives are kappa B kinase inhibitors, useful to treat or prevent e.g. inflammatory diseases, diabetes, cancer resistant to cytotoxic agents, solid or liquid tumors and in cancer chemotherapy |
WO2007006926A3 (en) * | 2005-07-11 | 2007-03-22 | Sanofi Aventis | Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors |
WO2007006926A2 (en) * | 2005-07-11 | 2007-01-18 | Sanofi-Aventis | Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors |
US7563787B2 (en) | 2005-09-30 | 2009-07-21 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
US8114870B2 (en) | 2005-09-30 | 2012-02-14 | Miikana Therapeutics, Inc. | Method of treating disease states using substituted pyrazole compounds |
US8404692B2 (en) | 2005-10-14 | 2013-03-26 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds |
US8088784B2 (en) | 2005-10-28 | 2012-01-03 | Astrazeneca Ab | 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20110212077A1 (en) * | 2005-11-01 | 2011-09-01 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
AU2006309013B2 (en) * | 2005-11-01 | 2012-06-28 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
AU2012230091B2 (en) * | 2005-11-01 | 2015-04-23 | Impact Biomedicines, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US7705009B2 (en) | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
WO2007071455A1 (en) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine-substituted pyrimidines , their preparation and use as drugs |
US7825128B2 (en) | 2005-12-22 | 2010-11-02 | Bayer Schering Pharma Ag | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs |
US9598669B2 (en) | 2005-12-29 | 2017-03-21 | Anthrogenesis Corporation | Composition for collecting placental stem cells and methods of using the composition |
US9725694B2 (en) | 2005-12-29 | 2017-08-08 | Anthrogenesis Corporation | Composition for collecting and preserving placental stem cells and methods of using the composition |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US11667611B2 (en) | 2006-02-24 | 2023-06-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US9573942B2 (en) | 2006-03-30 | 2017-02-21 | Janssen Sciences Ireland Uc | HIV inhibiting 5-amido substituted pyrimidines |
US8933089B2 (en) | 2006-03-30 | 2015-01-13 | Janssen R & D Ireland | HIV inhibiting 5-amido substituted pyrimidines |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
WO2008049123A2 (en) | 2006-10-19 | 2008-04-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
US8399450B2 (en) | 2006-12-08 | 2013-03-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8377921B2 (en) | 2006-12-08 | 2013-02-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8372858B2 (en) | 2006-12-08 | 2013-02-12 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8957081B2 (en) | 2006-12-08 | 2015-02-17 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8039479B2 (en) | 2006-12-08 | 2011-10-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8318736B2 (en) | 2006-12-29 | 2012-11-27 | Janssen R&D Ireland | HIV inhibiting 5,6-substituted pyrimidines |
US9006243B2 (en) | 2006-12-29 | 2015-04-14 | Janssen R&D Ireland | HIV inhibiting 6-substituted pyrimidines |
WO2008111441A1 (en) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
US8486966B2 (en) | 2007-05-04 | 2013-07-16 | Astrazeneca Ab | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer |
US8598361B2 (en) | 2007-07-31 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof |
WO2009105675A1 (en) | 2008-02-22 | 2009-08-27 | Rigel Pharmaceuticals, Inc. | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
US8530466B2 (en) | 2008-02-22 | 2013-09-10 | Rigel Pharmaceuticals, Inc. | Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis |
US11414410B2 (en) | 2008-04-16 | 2022-08-16 | Alexion Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8501944B2 (en) | 2008-04-16 | 2013-08-06 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9579320B2 (en) | 2008-04-16 | 2017-02-28 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US8952027B2 (en) | 2008-04-16 | 2015-02-10 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US10533001B2 (en) | 2008-04-16 | 2020-01-14 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
US8937070B2 (en) | 2008-04-16 | 2015-01-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9868729B2 (en) | 2008-04-16 | 2018-01-16 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9139581B2 (en) | 2008-04-22 | 2015-09-22 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
WO2010038081A3 (en) * | 2008-10-03 | 2010-05-27 | Astrazeneca Ab | 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors |
EP2179991A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179993A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
EP2179992A1 (en) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
US9150546B2 (en) | 2009-02-13 | 2015-10-06 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical composition comprising the same |
US9688643B2 (en) | 2009-02-13 | 2017-06-27 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical composition comprising the same |
DE102009001438A1 (en) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome |
DE102009015070A1 (en) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | New phenyl-pyrimidin-2-yl-amine compounds are tyrosine kinase 2 inhibitors useful for treating e.g. rheumatoid arthritis, Crohn's disease, asthma, multiple sclerosis, adult respiratory distress syndrome, allergic alveolitis and uveitis |
EP2473486B1 (en) | 2009-09-02 | 2015-10-28 | Vifor (International) Ag | Pyrimidines as hepcidine antagonists |
WO2011065800A2 (en) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same |
WO2011065800A3 (en) * | 2009-11-30 | 2011-10-27 | 주식회사 오스코텍 | Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same |
DE102010014426A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Use of new pan-CDK inhibitors for the treatment of tumors |
DE102010014427A1 (en) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Combination, to treat e.g. tumors e.g. breast cancer, and psoriasis comprises substituted N-(4-hydrosulfonimidoylphenyl)-5-(trifluoromethyl)pyrimidin-2-amine compounds and antihyperproliferative, cytostatic or cytotoxic substances |
US9375402B2 (en) | 2010-06-29 | 2016-06-28 | Verastem, Inc. | Oral formulations of kinase inhibitors |
US9505719B2 (en) | 2010-06-30 | 2016-11-29 | Verastem, Inc. | Synthesis and use of kinase inhibitors |
US9718790B2 (en) | 2010-08-10 | 2017-08-01 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same |
US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
EP3176154A1 (en) | 2010-11-01 | 2017-06-07 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
WO2012061418A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
US10391094B2 (en) | 2010-11-07 | 2019-08-27 | Impact Biomedicines, Inc. | Compositions and methods for treating myelofibrosis |
US9174946B2 (en) | 2011-02-17 | 2015-11-03 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
US9421205B2 (en) | 2011-02-17 | 2016-08-23 | Cancer Therapeutics CRC Pty Ltd. | FAK inhibitors |
US9012461B2 (en) | 2011-02-17 | 2015-04-21 | Cancer Therapeutics Crc Pty Ltd | FAK inhibitors |
US9120761B2 (en) | 2011-02-17 | 2015-09-01 | Cancer Therapeutics Crc Pty Ltd | Selective FAK inhibitors |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US9550763B2 (en) | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
WO2013139734A1 (en) | 2012-03-21 | 2013-09-26 | Bayer Intellectual Property Gmbh | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours |
US10150743B2 (en) | 2012-05-18 | 2018-12-11 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
US9376398B2 (en) | 2012-05-18 | 2016-06-28 | Sumitomo Dainippon Pharma Co., Ltd | Carboxylic acid compounds |
US11299465B2 (en) | 2012-05-18 | 2022-04-12 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
US10562861B2 (en) | 2012-05-18 | 2020-02-18 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
WO2014085225A1 (en) * | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
US9738651B2 (en) | 2013-03-15 | 2017-08-22 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US10633389B2 (en) | 2013-03-15 | 2020-04-28 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
WO2014144169A1 (en) * | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US9856267B2 (en) | 2013-03-15 | 2018-01-02 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US11834455B2 (en) | 2013-03-15 | 2023-12-05 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US10118931B2 (en) | 2013-03-15 | 2018-11-06 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
US10065941B2 (en) | 2013-06-14 | 2018-09-04 | Shionogi & Co., Ltd. | Aminotriazine derivative and pharmaceutical composition comprising the same |
US9732060B2 (en) | 2013-06-14 | 2017-08-15 | Shionogi & Co., Ltd. | Aminotriazine derivative and pharmaceutical composition comprising the same |
US11560352B2 (en) | 2015-06-11 | 2023-01-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | P62-ZZ small molecule modulators |
AU2020260512B2 (en) * | 2015-06-11 | 2022-07-21 | Xiangqun Xie | P62-zz chemical inhibitor |
WO2019177375A1 (en) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-substituted pyrimidine derivatives, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
WO2023214772A1 (en) * | 2022-05-03 | 2023-11-09 | 한국화학연구원 | Compound including 2,4-diaminopyridine, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer |
CN115677595A (en) * | 2022-10-26 | 2023-02-03 | 江苏睿实生物科技有限公司 | Preparation method of 2,4, 5-trichloropyrimidine |
Also Published As
Publication number | Publication date |
---|---|
BR9916590A (en) | 2001-10-23 |
DE69920509T2 (en) | 2006-03-09 |
KR20010099900A (en) | 2001-11-09 |
NO319815B1 (en) | 2005-09-19 |
CN1285580C (en) | 2006-11-22 |
DK1140860T3 (en) | 2005-01-10 |
KR100663773B1 (en) | 2007-01-03 |
NZ512118A (en) | 2003-08-29 |
PT1140860E (en) | 2005-01-31 |
JP2002533446A (en) | 2002-10-08 |
ES2228145T3 (en) | 2005-04-01 |
US6593326B1 (en) | 2003-07-15 |
EP1140860B1 (en) | 2004-09-22 |
NO20013038D0 (en) | 2001-06-19 |
EP1140860A1 (en) | 2001-10-10 |
AU763091B2 (en) | 2003-07-10 |
IL143806A (en) | 2009-06-15 |
CN1335838A (en) | 2002-02-13 |
DE69920509D1 (en) | 2004-10-28 |
IL143806A0 (en) | 2002-04-21 |
ATE277020T1 (en) | 2004-10-15 |
GB9828511D0 (en) | 1999-02-17 |
AU1874300A (en) | 2000-07-31 |
ZA200104413B (en) | 2002-08-29 |
CA2352896A1 (en) | 2000-07-06 |
NO20013038L (en) | 2001-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1140860B1 (en) | Pyrimidine compounds | |
EP1161428B1 (en) | Pyrimidine compounds | |
CA2398887C (en) | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | |
US6649608B2 (en) | 2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | |
AU2001235768A1 (en) | Pyrimidine compounds | |
EP1286972A1 (en) | Pyrimidine compounds | |
AU2001233979A1 (en) | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | |
WO2000059892A1 (en) | Pyrimidine compounds with pharmaceutical activity | |
EP1272477A1 (en) | Pyrimidine compounds | |
MXPA01006575A (en) | Pyrimidine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99816278.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2352896 Country of ref document: CA Ref document number: 2352896 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/04413 Country of ref document: ZA Ref document number: 200104413 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18743/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999962375 Country of ref document: EP Ref document number: 512118 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 143806 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2000 591012 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/006575 Country of ref document: MX Ref document number: 1020017007971 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868602 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999962375 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017007971 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 18743/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999962375 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017007971 Country of ref document: KR |